Method and detector for identifying subtypes of human papilloma viruses

Abstract

A detector for detecting and simultaneously diagnosing at least one subtype of human papilloma viruses (HPV) contained in a biological sample is provided. The detector comprises: a carrier, a plurality of micro-dots immobilized on the carrier, wherein each micro-dot is for identifying one particular HPV subtype, and the HPV subtype is one selected from a group consisting of 39 different HPV subtypes; and at least one oligonucleotide sequence contained in each the micro-dot that is specific to the one particular HPV subtype, wherein the at least one oligonucleotide sequence serves as a detection probe that hybridizes specifically with an L1 gene sequence of the one particular HPV subtype to form a hybridization complex as a detection indicator, so that each micro-dot identifies one particular HPV subtype via a corresponding oligonucleotide of the one particular HPV subtype, and thereby detecting and simultaneously identifying subtypes of human papilloma viruses.

Description

FIELD OF THE INVENTION

The present invention relates to a method and a detector for detecting human papilloma viruses, and more particularly to a method and a detector for simultaneously detecting and identifying subtype of human papilloma viruses (HPV).

BACKGROUND OF THE INVENTION

In humans, more than 70 genetically distinct strains of human papilloma virus (HPV) have been identified based on DNA hybridization studies. According to some reports, different HPV types cause distinct diseases. For example, “Low-risk” HPVs, e.g., HPV 6 and HPV 11, cause benign hyperplasias such as genital warts, while “high-risk” HPVs, e.g., HPV-16, HPV-18, HPV-31, HPV-33, HPV-54, and the like, can cause cancers such as cervical or penile carcinoma.

Cervical cancer is the most common cancer in women. The consorts are often men with penile warts. Sexual activity appears to be an important predisposing factor of the epidemic disease and precancerous lesions. In early 5 to 10 years during the development of cervical cancer, cervical cells form cervical intraepithelial neoplasm.

Recently, in order to decrease the incidence of cervical cancer, Pap smear is used for the cervical cancer screening. However, the Pap smear has a false negative rate of about 30%˜40%. In addition, it is known that more that 95% of cervical carcinoma tissue contain detectable DNA sequences for known varieties of the human papilloma virus (HPV). Hence, the combination of Pap smear and HPV detection for the cervical cancer screening is necessarily considered.

The Applicant cooperates with the hospital to do the epidemiological research in women cervical cancer by using Pap smear and HPV detection, wherein the HPV detection is proceeded by using polymerase chain reaction and nucleotide sequencing. There are 2424 women aged from 16 to 84 for the epidemiology research, wherein 1963 women provide the effective specimen. The research results are shown as follows.

• • 1) 1.9% (37/1963) of the women have abnormal cytological smears.
  • 2) 12.7% (244/1926) of the women with normal cytological smears but have HPV infection.
  • 3) The HPV prevalence in the women with abnormal cytological smears is 51.4% (19/37) and positively relative to the degree of the abnormal cytological smears, wherein the incidence of abnormal non-typical squamous cells is 23.1%, the incidence of low abnormal epithelial cells is 41.7%, and the incidence of high abnormal epithelial cells is 75%.
  • 4) The subtypes of human papilloma viruses detected in the specimens are HPV 52, HPV 58, HPV 70, HPV 16, HPV 18, HPV 68, HPV 33, HPV 66, HPV 35, HPV 37, HPV 54, HPV 59, HPV 67, HPV 72, HPV 69, HPV 82, HPV 39, HPV 31, HPV 32, HPV HLT7474-S, HPV 6, HPV CP8061, HPV 62, HPV CP8304, HPV 44, HPV 11, HPV 61, HPV 74, HPV 42 and HPV 43.

The conventional HPV detecting kits are only used for detecting 18 subtypes of human papilloma viruses including high risk HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59 and HPV 68, and detecting low risk HPV 6, HPV 11, HPV 42, HPV 43 and HPV 44.

However, according to the comparison of the epidemiology research and the conventional HPV detecting kits, several clinically-important subtypes of human papilloma viruses contained in a specimen could not be identified by the conventional HPV detecting kits. In addition, the conventional HPV detecting kits only tell the information of HPVs contained in a specimen by two categories, high risk HPVs or low HPVs, rather than tell the definite subtypes as which they are classified. Therefore, except the high risk HPVs and the low risk HPVs, if other HPV subtypes are contained in the specimen, the conventional HPV detecting kits can not identify immediately, which would seriously affects the diagnosis accuracy. Furthermore, the conventional HPV detecting kits lack the system control for checking the house-keeping genes contained in a specimen. Without the system control, it will be hard to confirm whether the detecting protocols are precisely followed. That is, the user can not tell the positive/negative result comes from the HPV subtypes presence/absence or comes from the incorrect protocols execution. Therefore, the conventional detecting kit without the system control would not be able to provide a convincing result.

From the above description, it is known that the conventional detecting kit can not identify many HPV subtypes at the same time and it does not include an internal control in the detecting system. Therefore, how to simultaneously detect many HPV subtypes contained in a biological simple and design an accurate internal control in the detecting kits have become a major problem waited to be solved. In order to overcome the foresaid drawbacks of the conventional HPV detecting kits, the present invention provides a method and a detector for simultaneously detecting and identifying subtypes of human papilloma viruses contained in a sample.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide a detector for simultaneously detecting and identifying subtypes of human papilloma viruses (HPV) contained in a sample.

The main purpose of the present invention is to provide a HPV detecting kit, which is able to diagnose multiple HPV subtypes (up to 39 different subtypes) at the same time, allowing the rapid and reliable detection and identification of HPV possibly present in a biological sample.

It is another object of the present invention to provide a rapid and reliable method to detect and identify the HPV present in a biological sample.

It is another object of the present invention to provide a HPV detecting kit with high specificity and accuracy, which includes an internal control to show whether the detecting process is well handled so that the detecting result is dependable.

It is another object of the present invention to provide a number of oligonucleotides as probes for detecting and identifying the HPV present in a biological sample.

According to one aspect of the present invention, a detector for detecting and simultaneously diagnosing at least one subtype of human papilloma viruses (HPV) contained in a biological sample, comprises: a carrier, a plurality of micro-dots immobilized on the carrier, wherein each micro-dot is for identifying one particular HPV subtype, and the HPV subtype is one selected from a group consisting of (HPV 6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 32, HPV 33, HPV 35, HPV 37, HPV 39, HPV 42, HPV 43, HPV 44, HPV 45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 62, HPV 66, HPV 67, HPV 68, HPV 69, HPV 70, HPV 72, HPV 74, HPV 82, HPV CP8061, HPV CP8034, HPV L1AE5, HPV MM4, HPV MM7 and HPV MM8); and at least one oligonucleotide sequence contained in each the micro-dot that is specific to the one particular HPV subtype, wherein the at least one oligonucleotide sequence serves as a detection probe that hybridizes specifically with an L1 gene sequence of the one particular HPV subtype to form a hybridization complex as a detection indicator, so that each micro-dot identifies one particular HPV subtype via a corresponding oligonucleotide of the one particular HPV subtype, and thereby detecting and simultaneously identifying subtypes of human papilloma viruses.

In accordance with the present invention, the at least one oligonucleotide that hybridizes specifically with an L1 gene sequence of the one particular HPV subtype is respectively chosen from the following list for each HPV subtype: (SEQ ID NO:1-SEQ ID NO:12) for HPV 6, (SEQ ID NO:13-SEQ ID NO:24) for HPV 11, (SEQ ID NO:25-SEQ ID NO:36) for HPV 16, (SEQ ID NO:37-SEQ ID NO:48) for HPV 18, (SEQ ID NO:49-SEQ ID NO:58) for HPV 26, (SEQ ID NO:59-SEQ ID NO:68) for HPV 31, (SEQ ID NO:69-SEQ ID NO:79) for HPV 32, (SEQ ID NO:80-SEQ ID NO:90) for HPV 33, (SEQ ID NO:91-SEQ ID NO:100) for HPV 35, (SEQ ID NO:101-SEQ ID NO:112) for HPV 37, (SEQ ID NO:113-SEQ ID NO:123) for HPV 39, (SEQ ID NO:124-SEQ ID NO:133) for HPV 42, (SEQ ID NO:134-SEQ ID NO:143) for HPV 43, (SEQ ID NO:144-SEQ ID NO:154) for HPV 44, (SEQ ID NO:155-SEQ ID NO:165) for HPV 45, (SEQ ID NO:166-SEQ ID NO:177) for HPV 51, (SEQ ID NO:178-SEQ ID NO:189) for HPV 52, (SEQ ID NO:190-SEQ ID NO:199) for HPV 53, (SEQ ID NO:200-SEQ ID NO:209) for HPV 54, (SEQ ID NO:210-SEQ ID NO:218) for HPV 55, (SEQ ID NO:219-SEQ ID NO:228) for HPV 56, (SEQ ID NO:229-SEQ ID NO:239) for HPV 58, (SEQ ID NO:240-SEQ ID NO:250) for HPV 59, (SEQ ID NO:251-SEQ ID NO:261) for HPV 61, (SEQ ID NO:262-SEQ ID NO:272) for HPV 62, (SEQ ID NO:273-SEQ ID NO:283) for HPV 66, (SEQ ID NO:284-SEQ ID NO:294) for HPV 67, (SEQ ID NO:295-SEQ ID NO:305) for HPV 68, (SEQ ID NO:306-SEQ ID NO:316) for HPV 69, (SEQ ID NO:317-SEQ ID NO:328) for HPV 70, (SEQ ID NO:329-SEQ ID NO:341) for HPV 72, (SEQ ID NO:342-SEQ ID NO:353) for HPV 74, (SEQ ID NO:354-SEQ ID NO:362) for HPV 82, (SEQ ID NO:363-SEQ ID NO:374) for HPV CP8061, (SEQ ID NO:375-SEQ ID NO:386) for HPV CP8034, (SEQ ID NO:387-SEQ ID NO:397) for HPV L1AE5, (SEQ ID NO:398-SEQ ID NO:408) for HPV MM4, (SEQ ID NO:409-SEQ ID NO:419) for HPV MM7, and (SEQ ID NO:420-SEQ ID NO:429) for HPV MM8.

Preferably, the carrier is a nylon membrane.

Preferably, the carrier is a glass plate.

Preferably, the detector is an oligonucleotide biochip.

Preferably, the at least one oligonucleotide has a length between 15-30 bases.

Preferably, the detector further comprises a micro-dot containing a Glutaldehyde-3-phosphodehydrogenase (GAPDH) gene, which is used as an internal control.

According to another aspect of the present invention, a method for detecting and simultaneously diagnosing at least one subtype of human papilloma viruses (HPV) contained in a biological sample is provided. The detecting method comprises steps of: amplifying an L1 gene fragment of human papilloma viruses (HPV) contained in the biological sample and obtaining an amplification product by polymerase chain reaction (PCR) using primers labeled with signaling substance; hybridizing the amplification product with a detector according to claim 1 to form a hybridization complex; removing nonhybridized the amplification product; and detecting the hybridization complex through detecting the signaling substance, thereby detecting and simultaneously identifying HPV subtypes contained in the biological sample.

Preferably, the amplification product has a length of 450 base pairs by using MY09 as sense primer and MY11 as anti-sense primer in polymerase chain reaction (PCR).

Preferably, the amplification product has a length of 190 base pairs by using MY11 as sense primer and GP6+ as anti-sense primer in polymerase chain reaction (PCR).

Preferably, the signaling substance is biotin.

Preferably, the biotin reacts with avidin-alkalinephosphatase to show the hybridization result by presenting a particular color.

Preferably, the signaling substance is a fluorescent substance.

Preferably, the fluorescent substance is Cyanine 5.

According to another aspect of the present invention, a probe which hybridizes to nucleic acid from an HPV subtype, the probe being selected from the group consisting of: SEQ ID NO:1-SEQ ID NO:12 and sequences fully complementary thereto, which hybridize with HPV 6; SEQ ID NO:13-SEQ ID NO:24 and sequences fully complementary thereto, which hybridize with HPV 11; SEQ ID NO:25-SEQ ID NO:36 and sequences fully complementary thereto, which hybridize with HPV 16; SEQ ID NO:37-SEQ ID NO:48 and sequences fully complementary thereto, which hybridize with HPV 18; SEQ ID NO:49-SEQ ID NO:58 and sequences fully complementary thereto, which hybridize with HPV 26; SEQ ID NO:59-SEQ ID NO:68 and sequences fully complementary thereto, which hybridize with HPV 31; SEQ ID NO:69-SEQ ID NO:79 and sequences fully complementary thereto, which hybridize with HPV 32; SEQ ID NO:80-SEQ ID NO:90 and sequences fully complementary thereto, which hybridize with HPV 33; SEQ ID NO:91-SEQ ID NO:100 and sequences fully complementary thereto, which hybridize with HPV 35; SEQ ID NO:101-SEQ ID NO:112 and sequences fully complementary thereto, which hybridize with HPV 37; SEQ ID NO:113-SEQ ID NO:123 and sequences fully complementary thereto, which hybridize with HPV 39; SEQ ID NO:124-SEQ ID NO:133 and sequences fully complementary thereto, which hybridize with HPV 42; SEQ ID NO:134-SEQ ID NO:143 and sequences fully complementary thereto, which hybridize with HPV 43; SEQ ID NO:144-SEQ ID NO:154 and sequences fully complementary thereto, which hybridize with HPV 44; SEQ ID NO:155-SEQ ID NO:165 and sequences fully complementary thereto, which hybridize with HPV 45; SEQ ID NO:166-SEQ ID NO:177 and sequences fully complementary thereto, which hybridize with HPV 51; SEQ ID NO:178-SEQ ID NO:189 and sequences fully complementary thereto, which hybridize with HPV 52; SEQ ID NO:190-SEQ ID NO:199 and sequences fully complementary thereto, which hybridize with HPV 53; SEQ ID NO:200-SEQ ID NO:209 and sequences fully complementary thereto, which hybridize with HPV 54; SEQ ID NO:210-SEQ ID NO:218 and sequences fully complementary thereto, which hybridize with HPV 55; SEQ ID NO:219-SEQ ID NO:228 and sequences fully complementary thereto, which hybridize with HPV 56; SEQ ID NO:229-SEQ ID NO:239 and sequences fully complementary thereto, which hybridize with HPV 58; SEQ ID NO:240-SEQ ID NO:250 and sequences fully complementary thereto, which hybridize with HPV 59; SEQ ID NO:251-SEQ ID NO:261 and sequences fully complementary thereto, which hybridize with HPV 61; SEQ ID NO:262-SEQ ID NO:272 and sequences fully complementary thereto, which hybridize with HPV 62; SEQ ID NO:273-SEQ ID NO:283 and sequences fully complementary thereto, which hybridize with HPV 66; SEQ ID NO:284-SEQ ID NO:294 and sequences fully complementary thereto, which hybridize with HPV 67; SEQ ID NO:295-SEQ ID NO:305 and sequences fully complementary thereto, which hybridize with HPV 68; SEQ ID NO:306-SEQ ID NO:316 and sequences fully complementary thereto, which hybridize with HPV 69; SEQ ID NO:317-SEQ ID NO:328 and sequences fully complementary thereto, which hybridize with HPV 70; SEQ ID NO:329-SEQ ID NO:341 and sequences fully complementary thereto, which hybridize with HPV 72; SEQ ID NO:342-SEQ ID NO:353 and sequences fully complementary thereto, which hybridize with HPV 74; SEQ ID NO:354-SEQ ID NO:362 and sequences fully complementary thereto, which hybridize with HPV 82; SEQ ID NO:363-SEQ ID NO:374 and sequences fully complementary thereto, which hybridize with HPV CP8061; SEQ ID NO:375-SEQ ID NO:386 and sequences fully complementary thereto, which hybridize with HPV CP8034; SEQ ID NO:387-SEQ ID NO:397 and sequences fully complementary thereto, which hybridize with HPV L1AE5; SEQ ID NO:398-SEQ ID NO:408 and sequences fully complementary thereto, which hybridize with HPV MM4; SEQ ID NO:409-SEQ ID NO:419 and sequences fully complementary thereto, which hybridize with HPV MM7; and SEQ ID NO:420-SEQ ID NO:429 and sequences fully complementary thereto, which hybridize with HPV MM8.

The foregoing and other features and advantages of the present invention will be more clearly understood through the following descriptions with reference to the drawings, wherein:

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic view showing the detector according to a preferred embodiment of the present invention;

FIG. 2(a) is a schematic view showing the detector according to a preferred embodiment of the present invention;

FIG. 2(b) is a schematic view illustrating the subtype of human papilloma viruses identified by each dot shown in FIG. 2(a);

FIG. 3(a) is the electrophoresis result showing the analyzed PCR products using primer set MY09/MY11 according to a preferred embodiment of the present invention;

FIG. 3(b) is the electrophoresis result showing the analyzed PCR products using primer set MY11/GP6+ according to a preferred embodiment of the present invention;

FIG. 3(c) is the electrophoresis result showing the analyzed PCR products using GAPDH primer set according to a preferred embodiment of the present invention;

FIG. 4(a) is the detecting result on the detector of detecting the PCR products using primer set MY09/MY11 of HPV positive clones according to a preferred embodiment of the present invention;

FIG. 4(b) is detecting result on the detector of detecting the PCR products using primer set MY11/GP6+of HPV positive clones according to a preferred embodiment of the present invention;

FIG. 5 is a view showing the detecting result on the detectors of detecting samples according to a preferred embodiment of the present invention;

FIG. 6(a) is a schematic view showing the detector according to another preferred embodiment of the present invention;

FIG. 6(b) is a schematic view illustrating the subtype of human papilloma viruses identified by each dot shown in FIG. 6(a);

FIG. 7(a) is a view showing the detector stained with SYBR Green II according to a embodiment of the present invention; and

FIG. 7(b) is a view showing the detecting result on the detectors of detecting samples according to a preferred embodiment of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention will now described more specifically with reference to the following embodiments. Papilloma viruses are small (50-60 nm), nonenveloped, and icosahedral DNA viruses. The DNA of many papilloma viruses, including over 50 human viruses, has been cloned and sequenced. Although there is a high degree of sequence divergence between species, all papilloma viruses share some common features of genome organization. The open reading frames (ORFs) of the virus genomes are designated an early region, a late region, and a long control region (LCR) of transcription. The early region contains genes E1-E8 (not all are present in all species), the late region contains genes L1 and L2 (where “E” denotes early and “L” denotes late), and the long control region (LCR) of transcription includes the promoter and enhancer for the viral early genes and the origin of replication. The early region encodes genes required for viral DNA replication, cellular proliferation, and, in some viruses, cellular transformation. The late region (about 3 kb) codes for the capsid proteins. L1 is the major capsid protein and is relatively well conserved among all the papilloma virus types. The L1 protein is about 500 amino acids in size. L1 probably induces the major humoral and cell-mediated responses to viral infection. The L2 proteins are about 500 amino acids in size, account for only a small proportion of the virion mass, and their function is not yet clear. The LCR region contains an origin of replication with binding sites for E1 and E2 and other cis acting sequences in the promoter and enhancer region.

Generally, PCR has been considered to be the most sensitive method for identifying HPV subtypes in biological samples. A number of different primer combinations amplifying DNA fragment from various regions of the HPV genome have been developed and used for the detection of HPV. However, primers amplifying DNA fragments in the conserved L1 region have become the most widely used in the clinical and epidemiological studies. It is because that certain region of the L1 gene presents a high degree of sequence variability in different HPV subtypes. In other words, the sequence variability among each HPV subtype could be the specific site for identifying each different HPV subtype.

In order to identify the various HPV subtypes, the Applicant focuses on the loci near the end of L1 gene to search the specific sequence variability as mentioned above. More specifically, the PCR fragment synthesized by the primer sets MY11/MY09 (as disclosed in Weimin et al., 1997, J. Clin. Microbiol. 35(6): 1304-1310) in the L1 region is the particular loci ranges where the Applicant refers to find the specific sequence variability for each HPV subtype in the present invention. Since the specific sequence variability for each HPV subtype is not only specific to a particular HPV subtype, but also distinguished from any other HPV subtype, consequently, the probes specifically hybridization with a particular HPV subtype could be selected for identifying or diagnosing HPV subtypes, which is also one of the main purposes of the present invention.

The PCR fragments synthesized by the primer sets MY11/MY09 in the L1 region are about 450 bp in length and had been published. The sequences of the fragments for each HPV subtype described in the invention are publicly available, for example, from the National Center for Biotechnology Information (NCBI) (e.g., www.ncbi.nih.gov). The 39 HPV subtypes identified in the invention includes HPV 6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 32, HPV 33, HPV 35, HPV 37, HPV 39, HPV 42, HPV 43, HPV 44, HPV 45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 62, HPV 66, HPV 67, HPV 68, HPV 69, HPV 70, HPV 72, HPV 74, HPV 82, HPV CP8061, HPV CP8034, HPV L1AE5, HPV MM4, HPV MM7 and HPV MM8. The original NCBI Accession number and the loci of the PCR fragments synthesized by the primer sets MY11/MY09 for different HPV subtypes are listed in Table 1:

TABLE 1
	Accession
HPV subtype	number/length(bp)	loci/length(bp)	SEQ ID NO.
HPV 6	NC_000904/8012	6743-7151/409	430
HPV 11	NC_001525/7931	6727-7135/409	431
HPV 16	NC_001526/7904	6602-7013/412	432
HPV 18	NC_001357/7857	6578-6992/415	433
HPV 26	NC_001583/7855	6553-6967/415	434
HPV 31	NC_001527/7912	6520-6931/412	435
HPV 32	NC_001586/7961	6837-7245/409	436
HPV 33	NC_001528/7909	6559-6967/409	437
HPV 35	NC_001529/7851	6542-6953/412	438
HPV 37	NC_001687/7421	6711-7125/415	439
HPV 39	NC_001535/7833	6605-7019/415	440
HPV 42	NC_001534/7917	6802-7210/409	441
HPV 43	U12504/455	21-435/415	442
HPV 44	NC_001689/7833	6647-7061/415	443
HPV 45	NC_001590/7858	6582-6996/415	444
HPV 51	NC_001533/7808	6486-6897/412	445
HPV 52	NC_001592/7942	6623-7031/409	446
HPV 53	NC_001593/7856	6614-7022/409	447
HPV 54	NC_001676/7759	6561-6972/412	448
HPV 55	NC_001692/7822	6647-7061/415	449
HPV 56	NC_001594/7844	6559-6967/409	450
HPV 58	NC_001443/7824	6608-7016/409	451
HPV 59	NC_001635/7896	6571-6985/415	452
HPV 61	NC_001694/7989	6732-7146/415	453
HPV 62	U12499/449	21-429/409	454
HPV 66	NC_001695/7824	6609-7017/409	455
HPV 67	D21208/7801	6584-6992/409	456
HPV 68	M73258/6042	2582-2996/415	457
HPV 69	NC 002171/7700	6509-6923/415	458
HPV 70	NC 001711/7905	6549-6963/415	459
HPV 72	X94164/7988	6758-7172/415	460
HPV 74	U40822/3891	1613-2027/415	461
HPV 82	AB027021/7871	6536-6950/415	462
HPV CP8061	U12479/452	21-432/412	463
HPV CP8304	U12480/452	21-432/412	464
HPV L1AE5	AF039910/364	11-360/350	465
HPV MM4	U12488/455	21-435/415	466
HPV MM7	U12489/452	21-432/412	467
HPV MM8	U12490/452	21-432/412	468

The sequences of the fragments of each HPV subtype described in the invention are listed below:

Human Papilloma Virus subtype 6 (6743-7151/409 bp)
tatttgttgg ggtaatcaac tgtttgttac tgtggtagat accacacgca gtaccaacat	60	SEQ ID NO 430
gacattatgt gcatccgtaa ctacatcttc cacatacacc aattctgatt ataaagagta	120
catgcgtcat gtggaagagt atgatttaca atttattttt caattatgta gcattacatt	180
gtctgctgaa gtaatggcct atattcacac aatgaatccc tctgttttgg aagactggaa	240
ctttgggtta tcgcctcccc caaatggtac attagaagat acctataggt atgtgcagtc	300
acaggccatt acctgtcaaa agcccactcc tgaaaaggaa aagccagatc cctataagaa	360
ccttagtttt tgggaggtta atttaaaaga aaagttttct agtgaattg	409
Human Papilloma Virus subtype 11 (6727-7135/409 bp)
tatttgctgg ggaaaccact tgtttgttac tgtggtagat accacacgca gtacaaatat	60	SEQ ID NO 431
gacactatgt gcatctgtgt ctaaatctgc tacatacact aattcagatt ataaggaata	120
catgcgccat gtggaggagt ttgatttaca gtttattttt caattgtgta gcattacatt	180
atctgcagaa gtcatggcct atatacacac aatgaatcct tctgttttgg aggactggaa	240
ctttggttta tcgcctccac caaatggtac actggaggat acttatagat atgtacagtc	300
acaggccatt acctgtcaga aacccacacc tgaaaaagaa aaacaggatc cctataagga	360
tatgagtttt tgggaggtta acttaaaaga aaagttttca agtgaatta	409
Human Papilloma Virus subtype 16 (6602-7013/412 bp)
catttgttgg ggtaaccaac tatttgttac tgttgttgat actacacgca gtacaaatat	60	SEQ ID NO 432
gtcattatgt gctgccatat ctacttcaga aactacatat aaaaatacta actttaagga	120
gtacctacga catggggagg aatatgattt acagtttatt tttcaactgt gcaaaataac	180
cttaactgca gacgttatga catacataca ttctatgaat tccactattt tggaggactg	240
gaattttggt ctacaacctc ccccaggagg cacactagaa gatacttata ggtttgtaac	300
ccaggcaatt gcttgtcaaa aacatacacc tccagcacct aaagaagatg atccccttaa	360
aaaatacact ttttgggaag taaatttaaa ggaaaagttt tctgcagacc ta	412
Human Papilloma Virus subtype 18 (6587-6992/415 bp)
tgtttgctgg cataatcaat tatttgttac tgtggtagat accactccca gtaccaattt	60	SEQ ID NO 433
aacaatatgt gcttctacac agtctcctgt acctgggcaa tatgatgcta ccaaatttaa	120
gcagtatagc agacatgttg aggaatatga tttgcagttt atttttcagt tgtgtactat	180
tactttaact gcagatgtta tgtcctatat tcatagtatg aatagcagta ttttagagga	240
ttggaacttt ggtgttcccc cccccccaac tactagtttg gtggatacat atcgttttgt	300
acaatctgtt gctattacct gtcaaaagga tgctgcaccg gctgaaaata aggatcccta	360
tgataagtta aagttttgga atgtggattt aaaggaaaag ttttctttag actta	415
Human Papilloma Virus subtype 26 (6553-6967/415 bp)
tatctgttgg ggcaatcaat tgtttgttac ctgtgttgat accacccgca gtactaacct	60	SEQ ID NO 434
taccattagt acattatctg cagcatctgc atccactcca tttaaaccat ctgattataa	120
acaatttata agacatggcg aagaatatga attacaattt atatttcagt tgtgtaaaat	180
aacacttaca acagatgtta tggcttacat acatttaatg aatgcctcca tattggagga	240
ttggaatttt ggactaacct tacctcccac tgctagtttg gaagatgcct ataggtttat	300
taaaaactct gctactacct gtcagcgtaa cgcccctcct gtgccaaagg aagatccttt	360
tcaaaaattt aaattttggg atgtagattt aaaagaaaaa ttttctattg atttg	415
Human Papilloma Virus subtype 31 (6520-6931/412 bp)
tatttgttgg ggcaatcagt tatttgttac tgtggtagat accacacgta gtaccaatat	60	SEQ ID NO 435
gtctgtttgt gctgcaattg caaacagtga tactacattt aaaagtagta attttaaaga	120
gtatttaaga catggtgagg aatttgattt acaatttata tttcagttat gcaaaataac	180
attatctgca gacataatga catatattca cagtatgaat cctgctattt tggaagattg	240
gaattttgga ttgaccacac ctccctcagg ttctttggag gatacctata ggtttgtcac	300
ctcacaggcc attacatgtc aaaaaactgc cccccaaaag cccaaggaag atccatttaa	360
agattatgta ttttgggagg ttaatttaaa agaaaagttt tctgcagatt ta	412
Human Papilloma Virus subtype 32 (6837-7245/409 bp)
tatatgttgg ggtaatcaag tgtttctaac tgttgtggat actacccgta gtactaacat	60	SEQ ID NO 436
gactgtgtgt gctactgtaa caactgaaga cacatacaag tctactaact ttaaggaata	120
tctacgccat gcagaggaat atgatataca gtttatattt caattgtgca aaattacatt	180
atctgtagag gttatgtcat atatccacac catgaatcct gacatactag acgattggaa	240
tgttggtgta gctccaccgc cctctggtac tttagaagat agttatagat ttgtgcagtc	300
tcaggccata cgatgtcaag ctaaggtaac agcacctgaa aaaaaggatc ctttttctga	360
ctattcattt tgggaagtaa atttatctga aaagttttct agtgattta	409
Human Papilloma Virus subtype 33 (6559-6967/409 bp)
tatttgttgg ggcaatcagg tatttgttac tgtggtagat accactcgca gtactaatat	60	SEQ ID NO 437
gactttatgc acacaagtaa ctagtgacag tacatataaa aatgaaaatt ttaaagaata	120
tataagacat gttgaagaat atgatctaca gtttgttttt caactatgca aagttacctt	180
aactgcagaa gttatgacat atattcatgc tatgaatcca gatattttag aagattggca	240
atttggttta acacctcctc catctgctag tttacaggat acctataggt ttgttacctc	300
tcaggctatt acgtgtcaaa aaacagtacc tccaaaggaa aaggaagacc ccttaggtaa	360
atatacattt tgggaagtgg atttaaagga aaaattttca gcagattta	409
Human Papilloma Virus subtype 35 (6542-6953/412 bp)
tatttgttgg agtaaccaat tgtttgttac tgtagttgat acaacccgta gtacaaatat	60	SEQ ID NO 438
gtctgtgtgt tctgctgtgt cttctagtga cagtacatat aaaaatgaca attttaagga	120
atatttaagg catggtgaag aatatgattt acagtttatt tttcagttat gtaaaataac	180
actaacagca gatgttatga catatattca tagtatgaac ccgtccattt tagaggattg	240
gaattttggc cttacaccac cgccttctgg taccttagag gacacatatc gctatgtaac	300
atcacaggct gtaacttgtc aaaaacccag tgcaccaaaa cctaaagatg atccattaaa	360
aaattatact ttttgggagg ttgatttaaa ggaaaagttt tctgcagact ta	412
Human Papilloma Virus subtype 37 (6711-7125/415 bp)
cattttatgg ggtaatcaaa tgtttatcac agttgctgat aatacacgga acacaaactt	60	SEQ ID NO 439
ttctattagt gtgtctactg acaatggcga agttacagaa tataattctc aaacactcag	120
agaataccta agacatgttg aagaatacca gctttcaatt attttacaac tttgtaaagt	180
tcctttaaag gctgaggttt taactcagat aaatgcaatg aattctggta tattggaaga	240
gtggcaatta ggatttgtac ctactccaga taattcagta catgaccttt ataggtacat	300
taattcaaag gctaccaagt gtcctgatgc agttgttgaa aaagaaaagg aagatccctt	360
tgcaaaatat acattttgga atgtagattt aactgaaaaa ttatcattgg attta	415
Human Papilloma Virus subtype 39 (6605-7017/415 bp)
tatatgttgg cataatcaat tatttcttac tgttgtggac actacccgta gtaccaactt	60	SEQ ID NO 440
tacattatct acctctatag agtcttccat accttctaca tatgatcctt ctaagtttaa	120
ggaatatacc aggcacgtgg aggagtatga tttacaattt atatttcaac tgtgtactgt	180
cacattaaca actgatgtta tgtcttatat tcacactatg aattcctcta tattggacaa	240
ttggaatttt gctgtagctc ctccaccatc tgccagtttg gtagacactt acagatacct	300
acagtctgca gccattacat gtcaaaagga tgctccagca cctgaaaaga aagatccata	360
tgacggtcta aagttttgga atgttgactt aagggaaaag tttagtttgg aactt	415
Human Papilloma Virus subtype 42 (6802-7210/409 bp)
tatatgttgg ggaaatcagc tatttttaac tgtggttgat actacccgta gtactaacat	60	SEQ ID NO 441
gactttgtgt gccactgcaa catctggtga tacatataca gctgctaatt ttaaggaata	120
tttaagacat gctgaagaat atgatgtgca atttatattt caattgtgta aaataacatt	180
aactgttgaa gttatgtcat atatacacaa tatgaatcct aacatattag aggagtggaa	240
tgttggtgtt gcaccaccac cttcaggaac tttagaagat agttataggt atgtacaatc	300
agaagctatt cgctgtcagg ctaaggtaac aacgccagaa aaaaaggatc cttattcaga	360
cttttggttt tgggaggtaa atttatctga aaagttttct actgattta	409
Human Papilloma Virus subtype 43 (21-435/415 bp)
catttgtttt gggaatcagt tgtttgttac agtggtagat accactcgta gtacaaactt	60	SEQ ID NO 442
gacgttatgt gcctctactg accctactgt gcccagtaca tatgacaatg caaagtttaa	120
ggaatacttg cggcatgtgg aagaatatga tctgcagttt atatttcaat tatgcataat	180
aacgctaaac ccagaggtta tgacatatat tcatactatg gatcccacat tattagagga	240
ctggaatttt ggtgtgtccc cacctgcctc tgcttctttg gaagatactt atcgcttttt	300
gtctaacaag gccattgcat gtcaaaaaaa tgctccccca aaggaacggg aggatcccta	360
taaaaagtat acattttggg atataaatct tacagaaaag ttttctgcac aactt	415
Human Papilloma Virus subtype 44 (6647-7061/415 bp)
tatttgttgg ggaaatcagt tatttgttac tgttgtagat actacccgta gtacaaacat	60	SEQ ID NO 443
gacaatatgt gctgccacta cacagtcccc tccgtctaca tatactagtg aacaatataa	120
gcaatacatg cgacatgttg aggagtttga cttacaattt atgtttcaat tatgtagtat	180
taccttaacg gcggaggtaa tggcctatct tcatactatg aatgctggta ttttagaaca	240
gtggaacttt gggttgtcgc cgcccccaaa tggtacctta gaggacaaat acagatatgt	300
gcagtcccag gccattacat gtcaaaagcc accccctgaa aaggcaaagc aggaccccta	360
tgcaaaatta agtttttggg aggtggatct tagagaaaag ttttctagtg agttg	415
Human Papilloma Virus subtype 45 (6582-6996/415 bp)
tatttgttgg cataatcagt tgtttgttac tgtagtggac actacccgca gtactaattt	60	SEQ ID NO 444
aacattatgt gcctctacac aaaatcctgt gccaagtaca tatgacccta ctaagtttaa	120
gcagtatagt agacatgtgg aggaatatga tttacagttt atttttcagt tgtgcactat	180
tactttaact gcagaggtta tgtcatatat ccatagtatg aatagtagta tattagaaaa	240
ttggaatttt ggtgtccctc caccacctac tacaagtttg gtggatacat atcgttttgt	300
gcaatcagtt gctgttacct gtcaaaagga tactacacct ccagaaaagc aggatccata	360
tgataaatta aagttttgga ctgttgacct aaaggaaaaa ttttcctccg atttg	415
Human Papilloma Virus subtype 51 (6486-6897/412 bp)
catttgctgg aacaatcagc tttttattac ctgtgttgat actaccagaa gtacaaattt	60	SEQ ID NO 445
aactattagc actgccactg ctgcggtttc cccaacattt actccaagta actttaagca	120
atatattagg catggggaag agtatgaatt gcaatttatt tttcaattat gtaaaattac	180
tttaactaca gaggtaatgg cttatttaca cacaatggat cctaccattc ttgaacagtg	240
gaattttgga ttaacattac ctccgtctgc tagtttggag gatgcatata ggtttgttag	300
aaatgcagct actagctgtc aaaaggacac ccctccacag gctaagccag atcctttggc	360
caaatataaa ttttgggatg ttgatttaaa ggaacgattt tctttagatt ta	412
Human Papilloma Virus subtype 52 (6623-7031/409 bp)
catatgttgg ggcaatcagt tgtttgtcac agttgtggat accactcgta gcactaacat	60	SEQ ID NO 446
gactttatgt gctgaggtta aaaaggaaag cacatataaa aatgaaaatt ttaaggaata	120
ccttcgtcat ggcgaggaat ttgatttaca atttattttt caattgtgca aaattacatt	180
aacagctgat gttatgacat acattcataa gatggatgcc actattttag aggactggca	240
atttggcctt accccaccac cgtctgcatc tttggaggac acatacagat ttgtcacttc	300
tactgctata acttgtcaaa aaaacacacc acctaaagga aaggaagatc ctttaaagga	360
ctatatgttt tgggaggtgg atttaaaaga aaagttttct gcagattta	409
Human Papilloma Virus subtype 53 (6614-7022/409 bp)
catctgttgg aacaatcagt tatttgtaac tgttgtggat accaccagga atacaaacat	60	SEQ ID NO 447
gactctttcc gcaaccacac agtctatgtc tacatataat tcaaagcaaa ttaaacagta	120
tgttagacat gcagaggaat atgaattaca atttgtgttt caactatgta aaatatccct	180
gtctgctgag gttatggcct atttacatac tatgaattct accttactgg aagactggaa	240
tataggtttg tcgcctcctg ttgccactag cttagaggac aaatacagat atgtgaaaag	300
tgcagctata acctgtcaaa aggatcagcc ccctcctgaa aagcaggacc cactatctaa	360
atataaattt tgggaggtca atttgcaaaa cagtttttct gctgatttg	409
Human Papilloma Virus subtype 54 (6561-6972/412 bp)
tatttgttgg ggcaatcagg tgtttttaac agttgtagat accacccgta gtactaacct	60	SEQ ID NO 448
aacattgtgt gctacagcat ccacgcagga tagctttaat aattctgact ttagggagta	120
tattagacat gtggaggaat atgatttaca gtttatattt cagttatgta ccataaccct	180
tacagcagat gttatggcct atattcatgg aatgaatccc actattctag aggactggaa	240
ctttggtata acccccccag ctacaagtag tttggaggac acatataggt ttgtacagtc	300
acaggccatt gcatgtcaaa agaataatgc ccctgcaaag gaaaaggagg atccttacag	360
taaatttaat ttttggactg ttgaccttaa ggaacgattt tcatctgacc tt	412
Human Papilloma Virus subtype 55 (6647-7061/415 bp)
tatttgttgg gggaatcagt tatttgttac tgttgtagat actacacgta gtacaaacat	60	SEQ ID NO 449
gacaatatgt gctgctacaa ctcagtctcc atctacaaca tataatagta cagaatataa	120
acaatacatg cgacatgttg aggagtttga cttacagttt atgtttcaat tatgtagtat	180
taccttaact gctgaggtaa tggcctattt acataccatg aatcctggta ttttggaaca	240
gtggaacttt gggttgtcgc cacccccaaa tggtacctta gaagacaaat acagatatgt	300
gcagtcacag gccattacat gtcaaaagcc tccccctgaa aaggcaaagc aggaccccta	360
tgcaaaatta agtttttggg aggtagatct cagagaaaag ttttctagtg agtta	415
Human Papilloma Virus subtype 56 (6559-6967/409 bp)
catttgctgg ggtaatcaat tatttgttac tgtagtagat actactagaa gtactaacat	60	SEQ ID NO 450
gactattagt actgctacag aacagttaag taaatatgat gcacgaaaaa ttaatcagta	120
ccttagacat gtggaggaat atgaattaca atttgttttt caattatgca aaattacttt	180
gtctgcagag gttatggcat atttacataa tatgaatgct aacctactgg aggactggaa	240
tattgggtta tccccgccag tggccaccag cctagaagat aaatatagat atgttagaag	300
cacagctata acatgtcaac gggaacagcc accaacagaa aaacaggacc cattagctaa	360
atataaattt tgggatgtta acttacagga cagtttttct acagacctg	419
Human Papilloma Virus subtype 58 (6608-7016/409 bp)
catttgctgg ggcaatcagt tatttgttac cgtggttgat accactcgta gcactaatat	60	SEQ ID NO 451
gacattatgc actgaagtaa ctaaggaagg tacatataaa aatgataatt ttaaggaata	120
tgtacgtcat gttgaagaat atgacttaca gtttgttttt cagctttgca aaattacact	180
aactgcagag ataatgacat atatacatac tatggattcc aatattttgg aggactggca	240
atttggttta acacctcctc cgtctgccag tttacaggac acatatagat ttgttacctc	300
ccaggctatt acttgccaaa aaacagcacc ccctaaagaa aaggaagatc cattaaataa	360
atatactttt tgggaggtta acttaaagga aaagttttct gcagatcta	409
Human Papilloma Virus subtype 59 (6571-6985/415 bp)
tatatgttgg cacaatcaat tgtttttaac agttgtagat actactcgca gcaccaatct	60	SEQ ID NO 452
ttctgtgtgt gcttctacta cttcttctat tcctaatgta tacacaccta ccagttttaa	120
agaatatgcc agacatgtgg aggaatttga tttgcagttt atatttcaac tgtgtaaaat	180
aacattaact acagaggtaa tgtcatacat tcataatatg aataccacta ttttggagga	240
ttggaatttt ggtgttacac cacctcctac tgctagttta gttgacacat accgttttgt	300
tcaatctgct gctgtaactt gtcaaaagga caccgcaccg ccagttaaac aggaccctta	360
tgacaaacta aagttttggc ctgtagatct taaggaaagg ttttctgcag atctt	415
Human Papilloma Virus subtype 61 (6732-7146/415 bp)
tatttgttgg tttaatgaat tgtttgtaac cgttgtggat accacccgca gtactaattt	60	SEQ ID NO 453
aaccatttgt actgctacat ccccccctgt atctgaatat aaagccacaa gctttaggga	120
atatttgcgc catacagagg agtttgattt gcaatttatt tttcagttat gtaaaataca	180
tttaacccct gaaattatgg cctacctaca taatatgaat aaggccttgt tggatgactg	240
gaactttggt gtggtaccac caccctctac cagtttagaa gacacatata ggtttttgca	300
gtccagagct attacatgtc agaagggtgc tgctgccccg ccgcccaagg aggatcgcta	360
tgccaagtta tccttttgga ctgttgattt acgagacaag ttttccactg atttg	415
Human Papilloma Virus subtype 62 (21-429/409 bp)
tatttgttgg tttaatgaac tgtttgttac tgtggtggat actaccagaa gtactaattt	60	SEQ ID NO 454
tactatttgt accgcctcca ctgctgcagc agaatacacg gctaccaact ttagggaatt	120
tttgcgacac acggaggaat ttgatttgca atttatattt caattgtgca aaatacagtt	180
aacccccgaa attatggcct acctgcataa tatgaacaag gaccttttgg atgactggaa	240
ctttggggtt ttacctcccc cttccactag tttagatgag acatatcact atttcgagtc	300
tcgggctatt acatgtcaaa gggggctgcc tacccgtccc aaggtggacc cgtatgcgca	360
aatgacattt tggactgtgg atcttaagga caagttgtct actgatttg	409
Human Papilloma Virus subtype 66 (6609-7017/409 bp)
catatgctgg ggtaatcagg tatttgttac tgttgtggat actaccagaa gcaccaacat	60	SEQ ID NO 455
gactattaat gcagctaaaa gcacattaac taaatatgat gcccgtgaaa tcaatcaata	120
ccttcgccat gtggaggaat atgaactaca gtttgtgttt caactttgta aaataacctt	180
aactgcagaa gttatggcat atttgcataa tatgaataat actttattag acgattggaa	240
tattggctta tccccaccag ttgcaactag cttagaggat aaatataggt atattaaaag	300
cacagctatt acatgtcaga gggaacagcc ccctgcagaa aagcaggatc ccctggctaa	360
atataagttt tgggaagtta atttacagga cagcttttct gcagacctg	409
Human Papilloma Virus subtype 67 (6584-6992/409 bp)
tatatgctgg ggtaatcaaa tatttgttac tgttgtagac actacacgta gtaccaacat	60	SEQ ID NO 456
gactttatgt tctgaggaaa aatcagaggc tacatacaaa aatgaaaact ttaaggaata	120
ccttagacat gtggaagaat atgatttgca gtttatattt cagctgtgca aaatatccct	180
tactgcaaat gttatgcaat acatacacac catgaatcca gatatattag aggactggca	240
atttggcctt acaccacctc cttcaggtaa tttacaggac acatatagat ttgttacctc	300
gcaggctatt acctgtcaaa aaacatcccc tccaacagca aaggaagatc ctcttaaaaa	360
gtacagtttt tgggaaatca atttaaagga aaaattttct gcagattta	409
Human Papilloma Virus subtype 68 (2582-2996/415 bp)
tatttgttgg cataatcaat tatttcttac tgttgtggat accactcgca gtaccaattt	60	SEQ ID NO 457
tactttgtct actactactg aatcagctgt accaaatatt tatgatccta ataaatttaa	120
ggaatatatt aggcatgttg aggaatatga tttgcaattt atatttcagt tgtgtactat	180
aacattgtcc actgatgtaa tgtcctatat acatactatg aatcctgcta ttttggatga	240
ttggaatttt ggtgttgccc ctccaccatc tgctagtctt gtagatacat accgctatct	300
gcaatcagca gcaattacat gtcaaaaaga cgcccctgca cctactaaaa aggatccata	360
tgatggctta aacttttgga atgtaaattt aaaggaaaag tttagttctg aactg	415
Human Papilloma Virus subtype 69 (6509-6923/415 bp)
catttgttgg ggcaaccaat tgtttgttac ttgtgtagat actacccgca gtaccaacct	60	SEQ ID NO 458
cactattagt actgtatctg cacaatctgc atctgccact tttaaaccat cagattataa	120
gcagtttata aggcatggtg aggaatatga attacagttt atatttcaat tgtgtaaaat	180
tactcttacc actgatgtaa tggcctatat ccatacaatg aattctacta ttttggaaaa	240
ttggaatttt ggccttacct tgcctcctac tgctagtttg gaagatgcat ataggtttat	300
taaaaattca gctactacat gtcaacgcga tgcccctgca cagcccaagg aggatccatt	360
tagtaaatta aaattttggg acgttgatct taaagaaaag ttttctattg attta	415
Human Papilloma Virus subtype 70 (6549-6963/415 bp)
catttgttgg cataaccagt tgtttattac tgtggtggac actacacgta gtactaattt	60	SEQ ID NO 459
tacattgtct gcctgcaccg aaacggccat acctgctgta tatagcccta caaagtttaa	120
ggaatatact aggcatgtgg aggaatatga tttacaattt atatttcaat tgtgtactat	180
cacattaact gctgacgtta tggcctacat ccatactatg aatcctgcaa ttttggacaa	240
ttggaatata ggagttaccc ctccaccatc tgcaagcttg gtggacacgt ataggtattt	300
acaatcagca gctatagcat gtcaaaagga tgctcctaca cctgaaaaaa aggatcccta	360
tgacgattta aaattttgga atgttgattt aaaggaaaag tttagtacag aacta	415
Human Papilloma Virus subtype 72 (6758-7172/415 bp)
catctgttgg tttaatgagc tttttgtgac agttgtagat actactcgca gtactaatgt	60	SEQ ID NO 460
aactatttgt actgccacag cgtcctctgt atcagaatat acagcttcta attttcgtga	120
gtatcttcgc cacactgagg aatttgattt gcagtttata tttcaactgt gtaaaattca	180
cttaactcct gaaattatgg cctacttgca caatatgaat aaggccttat tggatgactg	240
gaattttggt gtggtgcctc ctccttctac cagtttggat gatacctata ggtttttgca	300
gtctcgtgcc attacctgtc aaaagggggc tgccacccct cctcctaaag aagatccata	360
tgctaactta tccttttgga ctgtggattt aaaggacaaa ttttccactg acttg	415
Human Papilloma Virus subtype 74 (1613-2027/415 bp)
tatttgttgg ggtaatcaat tatttgttac agttgtggat accacacgca gtactaacat	60	SEQ ID NO 461
gactgtgtgt gctcctacct cacaatcgcc ttctgctaca tataatagtt cagactacaa	120
acaatacatg cgacatgtgg aggaatttga tttgcaattt atttttcaat tatgtagtat	180
taagttaact gctgaggtta tggcctatat tcatactatg aatcctacag ttttagaaga	240
gtggaacttt gggctaacgc ctccccccaa tggtacttta gaagacacct acagatatgt	300
gcagtcccag gctattacat gtcaaaaacc tacgcctgat aaagcaaagc ccaatcccta	360
tgcaaattta agtttttggg aagttaatct taaggaaaag ttttctagtg aatta	415
Human Papilloma Virus subtype 82 (6536-6950/415 bp)
catttgctgg aataatcagc tttttattac ttgtgttgac actactaaaa gtaccaattt	60	SEQ ID NO 462
aaccattagc actgctgtta ctccatctgt tgcacaaaca tttactccag caaactttaa	120
gcagtacatt aggcatgggg aagaatatga attgcaattt atatttcaat tgtgtaaaat	180
cactttaact actgaaatta tggcttacct gcacaccatg gattctacaa ttttagaaca	240
gtggaatttt ggattaacat tgcccccctc cgctagtttg gaggatgcct atcgatttgt	300
aaaaaatgca gcaacatcct gtcacaagga cagtcctcca caggctaaag aagacccttt	360
ggcaaaatat aaattttgga atgtagacct taaggaacgc ttttctttgg atttg	415
Human Papilloma Virus subtype CP8061 (21-432/412 bp)
catttgttgg ggcaatcagc tttttgtaac agttgtggac acatcacgta gtacaaatat	60	SEQ ID NO 463
gtccatctgt gctaccaaaa ctgttgagtc tacatataaa gcctctagtt tcatggaata	120
tttgagacat ggagaagaat ttgatttgca atttatattt caactatgtg ttattaattt	180
aacagctgaa attatggcct acttacatcg catggatgct acattactgg aggactggaa	240
tttttggttc ttaccacctc ctactgctag tcttggtgat acctaccgct ttttacagtc	300
tcaggccata acctgtcaga aaaacagtcc tcctcctgca gaaaaaaagg acccctatgc	360
agatcttaca ttttgggagg tggatttaaa ggagcggttt tcactagaat tg	412
Human Papilloma Virus subtype CP8304 (21-432/412 bp)
tatttgttgg tttaatgaaa tgtttgttac agtggtggat actaccagaa gcaccaattt	60	SEQ ID NO 464
tactatttgc acagctacat ctgctgctgc agaatacaag gcctctaact ttaaggaatt	120
tctgcgccat acagaggaat atgatttgca gtttattttc caattatgta aaatacagtt	180
aacaccagaa attatggcct acttacataa tatgaacaag gcactgttgg atgattggaa	240
ttttggtgtg ttgccacctc cttccaccag tttagatgac acatatcgct tttacagtc	300
tcgggccatt acctgtcaaa agggtgctgc tgcccctgcg cccaaagagg acccttatgc	360
cgacatgtca ttttggacag ttgaccttaa ggacaagttg tctactgatt tg	412
Human Papilloma Virus subtype L1AE5 (11-360/350 bp)
ggcacaacca attatttata actgtggtag acacaacacg tagtaccaat cttaccttat	60	SEQ ID NO 465
ctactgcaac tactaatcca gttccatcta tatatgaacc ttctaaattt aaggaataca	120
cacgccatgt agaggaatat gatttacaat ttatatttca attgtgtaaa attacactta	180
ctactgatgt tatgtcttat atacataaca tggatcctac tattttagat agttggaatt	240
ttggtgttag tcctccccca tctgctagct tagtagatac atataggttt ttacagtcat	300
ctgccattac atgtcagaag gatgtggttg ttccacaaaa aaaggatcca	350
Human Papilloma Virus subtype MM4 (21-435/415 bp)
catttgctgg aataatcagc tttttattac ttgtgttgac actactagaa gtaccaattt	60	SEQ ID NO 466
aaccattagc actgctgtta ctcaatctgt tgcacaaaca tttactccag caaactttaa	120
gcaatacatt aggcatgggg aagaatatga attgcaattt atatttcaat tgtgtaaaat	180
cactttaact actgaaatta tggcttacct gcacaccatg gattctacaa ttttagaaca	240
gtggaatttt ggattaacct tgcccccctc agctagtttg gaggatgcct atcgatttgt	300
aaaaaatgca gcaacatcct gtcacaagga cagtcctcca caggctaaac aagacccttt	360
ggcaaaatat aaattttgga atgtagacct taaggaacgc ttttctttgg atttg	415
Human Papilloma Virus subtype MM7 (21-432/412 bp)
catttgttgg tttaatgagt tatttgttac agttgtagat actacccgca gtaccaatat	60	SEQ ID NO 467
tactatttca gctgctgcta cacaggctaa tgaatacaca gcctctaact ttaaggaata	120
cctccgccac accgaggaat atgacttaca ggttatattg caactttgca aaatacatct	180
tacccctgaa attatggcat acctacatag tatgaatgaa catttattgg atgagtggaa	240
ttttggcgtg ttaccacctc cttccaccag ccttgatgat acctatcgct atctgcagtc	300
ccgtgctatt acctgccaaa agggtccttc cgcccctgcc cctaaaaagg atccttatga	360
tggccttgta ttttgggagg ttgatttaaa ggacaaacta tccacagatt tg	412
Human Papilloma Virus subtype MM8 (21-432/412 bp)
tatatgctgg tttaatcaat tgtttgtcac ggtggtggat accacccgca gcaccaattt	60	SEQ ID NO 468
tactattagt gctgctacca acaccgaatc agaatataaa cctaccaatt ttaaggaata	120
cctaagacat gtggaggaat atgatttgca gtttatattc cagttgtgta aggtccgtct	180
gactccagag gtcatgtcct atttacatac tatgaatgac tccttattag atgagtggaa	240
ttttggtgtt gtgccccctc cctccacaag tttagatgat acctataggt acttgcagtc	300
tcgcgccatt acttgccaaa agggggccgc cgccgccaag cctaaggaag atccttatgc	360
tggcatgtcc ttttgggatg tagatttaaa ggacaagttt tctactgatt tg	412

In order to find the specific probes for identifying or diagnosing HPV subtypes, some sequence analysis software are used for finding the variety sites among the above listed sequences of different HPV subtypes, e.g., DNASTAR. The above 450-bp sequences of 39 HPV subtypes are respectively divided into several fragments and analyzed by the software. Preferably, the genetic identify compared to other HPV subtypes must be lower than 30% for finding suitable probes with high specificity. After identifying the variety sites having low genetic identity in sequences of each HPV subtype, the probes for each HPV subtype are respectively designed to specifically hybridize with these variety sites. Then, the designed probes are tested for their specificities to the corresponding HPV subtypes respectively. Preferably, the probes are 15-30 base pairs in length: Ultimately, 9-12 probes with high specificity are found for each HPV subtype. The sequences of the probes for each HPV subtype are listed below.

HPV6
SEQ ID		Locus in
NO	5′→3′	HPV6
1	CATCCGTAACTACATCTTCC	6814-6833
2	ATCCGTAACTACATCTTCCA	6815-6834
3	CTACATCTTCCACATACACCAA	6823-6844
4	CATCTTCCACATACACCAAT	6826-6845
5	ATCTTCCACATACACCAATT	6827-6846
6	CCACATACACCAATTCTGAT	6832-6851
7	TAGCATTACATTGTCTGCTGAAG	6911-6933
8	TCCCTCTGTTTTGGAAGAC	6959-6977
09	GTTATCGCCTCCCCCAAATGGTACAT	6989-7014
10	CTATAGGTATGTGCAGTCACAG	7025-7046
11	GCCCACTCCTGAAAAGGAA	7064-7082
12	CTATAAGAACCTTAGT	7094-7109
HPV 11
SEQ ID		Locus in
NO	5′→3′	HPV 11
13	ATCTGTGTCTAAATC	6799-6813
14	TCTGTGTCTAAATCTGCTAC	6800-6819
15	ATCTGTGTCTAAATCTGCTACATACA	6799-6824
16	TGCATCTGTGTCTAAATCTG	6796-6815
17	AAATCTGCTACATACACTAA	6809-6828
18	CTAAATCTGCTACATACACTA	6807-6827
19	CTACATACACTAATTCAGAT	6816-6835
20	TAGCATTACATTATCTGCAGAAG	6895-6917
21	TCCTTCTGTTTTGGAGGAC	6943-6961
22	TTTATCGCCTCCACCAAATGGTACAC	6973-6998
23	TTATAGATATGTACAGTCACAGGCC	7009-7033
24	ACCCACACCTGAAAAAGAAAAAC	7048-7070
HPV 16
SEQ ID		Locus in
NO	5′→3′	HPV 16
25	TATGTCATTATGTGCTGCCA	6659-6678
26	GTGCTGCCATATCTACTTCA	6670-6689
27	TGCCATATCTACTTC	6674-6688
28	TATCTACTTCAGAAACTACA	6679-6698
29	CTACTTCAGAAACTACATATAA	6682-6703
30	ATAAAAATACTAACTTTAAG	6700-6719
31	CAAAATAACCTTAACTGCAGACG	6773-6795
32	TTCCACTATTTTGGAGGAC	6821-6839
33	TCTACAACCTCCCCCAGGAGGCACAC	6851-6876
34	TTATAGGTTTGTAACCCAG	6887-6905
35	ACATACACCTCCAGCACCT	6923-6941
36	CCTTAAAAAATACACT	6956-6971
HPV 18
SEQ ID		Locus in
NO	5′→3′	HPV 18
37	TTCTACACAGTCTCC	6650-6664
38	CAGTCTCCTGTACCTGGGCA	6657-6676
39	AGTCTCCTGTACCTGGGCAA	6658-6677
40	TCTCCTGTACCTGGGCAATATGA	6660-6682
41	CTGTACCTGGGCAATATGAT	6664-6683
42	ATGATGCTACCAAATTTAAG	6679-6698
43	TACTATTACTTTAACTGCAGATG	6752-6774
44	TAGCAGTATTTTAGAGGAT	6800-6818
45	TGTTCCCCCCCCCCCAACTACTAGTT	6830-6855
46	ATATCGTTTTGTACAATCTGTT	6866-6887
47	GGATGCTGCACCGGCTGAA	6905-6923
48	CTATGATAAGTTAAAG	6935-6950
HPV 26
SEQ ID		Locus in
NO	5′→3′	HPV 26
49	TAGTACATTATCTGCAGCAT	6619-6638
50	ATTATCTGCAGCATC	6625-6639
51	TGCAGCATCTGCATCCACTC	6631-6650
52	GCATCTGCATCCACTCCATTTAAA	6635-6658
53	CTCCATTTAAACCATCTGAT	6648-6667
54	TAAAATAACACTTACAACAGATG	6727-6749
55	TGCCTCCATATTGGAGGAT	6775-6793
56	ACTAACCTTACCTCCCACTGCTAGTT	6805-6830
57	CTATAGGTTTATTAAAAACTCT	6841-6862
58	TAACGCCCCTCCTGTGCCA	6880-6898
HPV 31
SEQ ID		Locus in
NO	5′→3′	HPV 31
59	TGCAATTGCAAACAG	6592-6606
60	GCAATTGCAAACAGTGATAC	6593-6612
61	CAATTGCAAACAGTGATACT	6594-6613
62	GCAAACAGTGATACTACATTTAA	6599-6621
63	CTACATTTAAAAGTAGTAAT	6612-6631
64	CAAAATAACATTATCTGCAGACA	6691-6713
65	TCCTGCTATTTTGGAAGAT	6739-6757
66	ATTGACCACACCTCCCTCAGGTTCTT	6769-6794
67	CTATAGGTTTGTCACCTCACAG	6805-6826
68	AACTGCCCCCCAAAAGCCC	6844-6862
HPV 32
SEQ ID		Locus in
NO	5′→3′	HPV 32
69	TGCTACTGTAACAACTGAAG	6906-6925
70	GCTACTGTAACAACTGAAGA	6907-6926
71	TACTGTAACAACTGA	6909-6923
72	ACTGTAACAACTGAAGACAC	6910-6929
73	CAACTGAAGACACATACAAGTC	6917-6938
74	CAAAATTACATTATCTGTAGAGG	7005-7027
75	TCCTGACATACTAGACGAT	7053-7071
76	TGTAGCTCCACCGCCCTCTGGTACTT	7083-7108
77	TTATAGATTTGTGCAGTCTCAG	7119-7140
78	TAAGGTAACAGCACCTGAA	7158-7176
79	TTTTTCTGACTATTCA	7188-7203
HPV 33
SEQ ID		Locus in
NO	5′→3′	HPV 33
80	TATGCACACAAGTAACTAGT	6624-6643
81	CACACAAGTAACTAG	6628-6642
82	ACAAGTAACTAGTGACAGTA	6631-6650
83	GTAACTAGTGACAGTACATATAA	6635-6657
84	GTACATATAAAAATGAAAAT	6648-6667
85	CAAAGTTACCTTAACTGCAGAAG	6727-6749
86	TCCAGATATTTTAGAAGAT	6775-6793
87	TTTAACACCTCCTCCATCTGCTAGTT	6805-6830
88	CTATAGGTTTGTTACCTCTCAG	6841-6862
89	AACAGTACCTCCAAAGGAA	6880-6898
90	CTTAGGTAAATATACA	6910-6925
HPV 35
SEQ ID		Locus in
NO	5′→3′	HPV 35
91	TCTGCTGTGTCTTCTAGTGA	6612-6631
92	TGCTGTGTCTTCTAG	6614-6628
93	GTGTCTTCTAGTGACAGTAC	6618-6637
94	CTTCTAGTGACAGTACATATAAA	6622-6644
95	GTACATATAAAAATGACAAT	6634-6653
96	TAAAATAACACTAACAGCAGATG	6713-6735
97	CCCGTCCATTTTAGAGGAT	6761-6779
98	CCTTACACCACCGCCTTCTGGTACCT	6791-6816
99	ATATCGCTATGTAACATCACAG	6827-6848
100	ACCCAGTGCACCAAAACCT	6866-6884
HPV 37
SEQ ID		Locus in
NO	5′→3′	HPV 37
101	TGTCTACTGACAATG	6782-6796
102	TGTCTACTGACAATGGCGAA	6782-6801
103	TGACAATGGCGAAGTTACAG	6789-6808
104	GACAATGGCGAAGTTACAGA	6790-6809
105	AATGGCGAAGTTACAGAATA	6793-6812
106	CAGAATATAATTCTCAAACA	6806-6825
107	TAAAGTTCCTTTAAAGGCTGAGG	6885-6907
108	TTCTGGTATATTGGAAGAG	6933-6951
109	ATTTGTACCTACTCCAGATAATTCAG	6963-6988
110	TTATAGGTACATTAATTCAAAG	6999-7020
111	TGCAGTTGTTGAAAAAGAA	7038-7056
112	CTTTGCAAAATATACA	7068-7083
HPV 39
SEQ ID		Locus in
NO	5′→3′	HPV 39
113	CTCTATAGAGTCTTC	6677-6691
114	TAGAGTCTTCCATACCTTCT	6682-6701
115	ATAGAGTCTTCCATACCTTC	6681-6700
116	GTCTTCCATACCTTCTACATATG	6686-6708
117	CTACATATGATCCTTCTAAG	6700-6719
118	TACTGTCACATTAACAACTGATG	6779-6801
119	TTCCTCTATATTGGACAA	6827-6844
120	TGTAGCTCCTCCACCATCTGCCAGTT	6857-6882
121	TTACAGATACCTACAGTCTGCA	6893-6914
122	GGATGCTCCAGCACCTGAA	6932-6950
123	ATATGACGGTCTAAAG	6962-6977
HPV 42
SEQ ID		Locus in
NO	5′→3′	HPV 42
124	TATATGTTGGGGAAATCAGCTA	6802-6823
125	CACTGCAACATCTGGTGATA	6874-6893
126	GCAACATCTGGTGATACATATACAGCTGCT	6878-6907
127	CATTAACTGTTGAAGTTATGTCA	6978-7000
128	CCTAACATATTAGAGGAGTGGAATGT	7019-7044
129	CACCACCACCTTCAGGAACT	7053-7072
130	GTTATAGGTATGTACAATCAGAAG	7083-7106
131	GCTAAGGTAACAACGCCAGAAAAAAAGGAT	7121-7150
132	CAGACTTTTGGTTTTGGGAGGTAA	7158-7181
133	GAAAAGTTTTCTACTGATTTA	7190-7210
HPV 43
SEQ ID		Locus in
NO	5′→3′	HPV 43
134	CATTTGTTTTGGGAATCAGTTG	21-42
135	TGACCCTACTGTGCCCAGTA	99-118
136	ACTGTGCCCAGTACATATGACAATGCAAAG	106-135
137	GTTTATATTTCAATTATGCATAA	177-199
138	CCAGAGGTTATGACATATATT	211-231
139	CCCACATTATTAGAGGACTGGAA	244-266
140	CCACCTGCCTCTGCTTCTTTG	280-300
141	CGCTTTTTGTCTAACAAGGCCATTG	313-337
142	CCAAAGGAACGGGAGGATCCCTA	358-380
143	CTTACAGAAAAGTTTTCTGCACAAC	409-433
HPV 44
SEQ ID		Locus in
NO	5′→3′	HPV 40
144	TGCCACTACACAGTC	6719-6733
145	CTACACAGTCCCCTCCGTCT	6724-6743
146	TGCCACTACACAGTCCCCTC	6719-6738
147	CAGTCCCCTCCGTCTACATATA	6729-6750
148	CTACATATACTAGTGAACAA	6742-6761
149	TAGTATTACCTTAACGGCGGAGG	6821-6843
150	TGCTGGTATTTTAGAACAG	6869-6887
151	GTTGTCGCCGCCCCCAAATGGTACCT	6899-6924
152	ATACAGATATGTGCAGTCCCAG	6935-6956
153	GCCACCCCCTGAAAAGGCA	6974-6992
154	CTATGCAAAATTAAGT	7004-7019
HPV 45
SEQ ID		Locus in
NO	5′→3′	HPV 45
155	TGCCTCTACACAAAATCCTG	6651-6670
156	CTCTACACAAAATCC	6654-6668
157	ACAAAATCCTGTGCCAAGTA	6660-6679
158	CAAAATCCTGTGCCAAGTAC	6661-6680
159	AATCCTGTGCCAAGTACATATG	6664-6685
160	GTACATATGACCCTACTAAG	6677-6696
161	CACTATTACTTTAACTGCAGAGG	6756-6778
162	TAGTAGTATATTAGAAAAT	6804-6822
163	TGTCCCTCCACCACCTACTACAAGTT	6834-6859
164	ATATCGTTTTGTGCAATCAGTT	6870-6891
165	GGATACTACACCTCCAGAA	6909-6927
HPV 51
SEQ ID		Locus in
NO	5′→3′	HPV 51
166	CACTGCCACTGCTGCGGTTT	6555-6574
167	TGCCACTGCTGCGGT	6558-6572
168	CACTGCTGCGGTTTCCCCAA	6561-6580
169	CCACTGCTGCGGTTTCCCCA	6560-6579
170	CTGCGGTTTCCCCAACATTTAC	6566-6587
171	CAACATTTACTCCAAGTAAC	6578-6597
172	TAAAATTACTTTAACTACAGAGG	6657-6679
173	TCCTACCATTCTTGAACAG	6705-6723
174	ATTAACATTACCTCCGTCTGCTAGTT	6735-6760
175	ATATAGGTTTGTTAGAAATGCA	6771-6792
176	GGACACCCCTCCACAGGCT	6810-6828
177	TTTGGCCAAATATAAA	6840-6855
HPV 52
SEQ ID		Locus in
NO	5′→3′	HPV 52
178	TGAGGTTAAAAAGGA	6695-6709
179	TGAGGTTAAAAAGGAAAGCA	6695-6714
180	GAGGTTAAAAAGGAAAGCAC	6696-6715
181	TTAAAAAGGAAAGCACATAT	6700-6719
182	AAAGGAAAGCACATATAAAAAT	6704-6725
183	GCACATATAAAAATGAAAAT	6712-6731
184	CAAAATTACATTAACAGCTGATG	6791-6813
185	TGCCACTATTTTAGAGGAC	6839-6857
186	CCTTACCCCACCACCGTCTGCATCTT	6869-6894
187	ATACAGATTTGTCACTTCTACT	6905-6926
188	AAACACACCACCTAAAGGA	6944-6962
189	TTTAAAGGACTATATG	6974-6989
HPV 53
SEQ ID		Locus in
NO	5′→3′	HPV 53
190	TCCGCAACCACACAGTCTAT	6681-6700
191	CCGCAACCACACAGT	6682-6696
192	CCGCAACCACACAGTCTATG	6682-6701
193	CACAGTCTATGTCTACATATAA	6691-6712
194	CTACATATAATTCAAAGCAA	6703-6722
195	TAAAATATCCCTGTCTGCTGAGG	6782-6804
196	TTCTACCTTACTGGAAGAC	6830-6848
197	TTTGTCGCCTCCTGTTGCCACTAGCT	6860-6885
198	ATACAGATATGTGAAAAGTGCA	6896-6917
199	GGATCAGCCCCCTCCTGAA	6935-6953
HPV 54
SEQ ID		Locus in
NO	5′→3′	HPV 54
200	TACAGCATCCACGCA	6633-6647
201	CAGCATCCACGCAGGATAGC	6635-6654
202	ACGCAGGATAGCTTTAATAA	6643-6662
203	CACGCAGGATAGCTTTAATA	6642-6661
204	ATAGCTTTAATAATTCTGAC	6650-6669
205	TACCATAACCCTTACAGCAGATG	6729-6751
206	TCCCACTATTCTAGAGGAC	6777-6795
207	TATAACCCCCCCAGCTACAAGTAGTT	6807-6832
208	ATATAGGTTTGTACAGTCACAG	6843-6864
209	GAATAATGCCCCTGCAAAGGAA	6882-6903
HPV 55
SEQ ID		Locus in
NO	5′→3′	HPV 55
210	TTTGTTACTGTTGTAGATACTAC	6669-6691
211	ATGACAATATGTGCTGCTAC	6705-6724
212	GACAATATGTGCTGCTACAA	6707-6726
213	TGCTACAACTCAGTCTCCAT	6719-6738
214	CTACAACTCAGTCTCCATCT	6721-6740
215	ACAACTCAGTCTCCATCTAC	6723-6742
216	ATGTTGAGGAGTTTGACTTA	6781-6800
217	TGTTGAGGAGTTTGACTTAC	6782-6801
218	TGAGGAGTTTGACTTACAGT	6785-6804
HPV 56
SEQ ID		Locus in
NO	5′→3′	HPV 56
219	CTGCTACAGAACAGT	6630-6644
220	GCTACAGAACAGTTAAGTAA	6632-6651
221	CAGAACAGTTAAGTAAATAT	6636-6655
222	GAACAGTTAAGTAAATATGATGC	6638-6660
223	GTAAATATGATGCACGAAAA	6648-6667
224	CAAAATTACTTTGTCTGCAGAGG	6727-6749
225	TGCTAACCTACTGGAGGAC	6775-6793
226	GTTATCCCCGCCAGTGGCCACCAGCC	6805-5830
227	ATATAGATATGTTAGAAGCACA	6841-6862
228	GGAACAGCCACCAACAGAA	6880-6898
HPV 58
SEQ ID		Locus in
NO	5′→3′	HPV 58
229	ATGCACTGAAGTAACTAAGG	6674-6693
230	CACTGAAGTAACTAAGGAAG	6677-6696
231	TGAAGTAACTAAGGA	6680-6694
232	GAAGTAACTAAGGAAGGTAC	6681-6700
233	CTAAGGAAGGTACATATAAAAA	6688-6709
234	ATAAAAATGATAATTTTAAG	6703-6722
235	CAAAATTACACTAACTGCAGAGA	6776-6798
236	TTCCAATATTTTGGAGGAC	6824-6842
237	TTTAACACCTCCTCCGTCTGCCAGTT	6854-6879
238	ATATAGATTTGTTACCTCCCAG	6890-6911
239	AACAGCACCCCCTAAAGAA	6929-6947
HPV 59
SEQ ID		Locus in
NO	5′→3′	HPV 59
240	TTCTACTACTTCTTC	6643-6657
241	ACTACTTCTTCTATTCCTAA	6647-6666
242	ACTTCTTCTATTCCTAATGT	6650-6669
243	TCTTCTATTCCTAATGTATACAC	6653-6675
244	ATGTATACACACCTACCAGT	6666-6685
245	TAAAATAACATTAACTACAGAGG	6745-6767
246	TACCACTATTTTGGAGGAT	6793-6811
247	TGTTACACCACCTCCTACTGCTAGTT	6823-6848
248	ATACCGTTTTGTTCAATCTGCT	6859-6880
249	GGACACCGCACCGCCAGTT	6898-6916
250	TTATGACAAACTAAAG	6928-6943
HPV 61
SEQ ID		Locus in
NO	5′→3′	HPV 61
251	CTGCTACATCCCCCC	6803-6817
252	ACATCCCCCCCTGTATCTGA	6808-6827
253	CATCCCCCCCTGTATCTGAA	6809-6828
254	CCCCTGTATCTGAATATAAAGC	6815-6836
255	CTGAATATAAAGCCACAAGC	6824-6843
256	TAAAATACATTTAACCCCTGAAA	6903-6925
257	TAAGGCCTTGTTGGATGAC	6951-6969
258	TGTGGTACCACCACCCTCTACCAGTT	6981-7006
259	ATATAGGTTTTTGCAGTCCAGA	7017-7038
260	GGGTGCTGCTGCCCCGCCGCCC	7056-7077
261	CTATGCCAAGTTATCC	7089-7104
HPV 62
SEQ ID		Locus in
NO	5′→3′	HPV 62
262	CCGCCTCCACTGCTG	92-106
263	GCCTCCACTGCTGCAGCAGA	94-113
264	CTGCTGCAGCAGAATACACG	101-120
265	GCAGAATACACGGCTACCAA	109-128
266	CAGAATACACGGCTACCAAC	110-129
267	CAAAATACAGTTAACCCCCGAAA	189-211
268	CAAGGACCTTTTGGATGAC	237-255
269	GGTTTTACCTCCCCCTTCCACTAGTT	267-292
270	ATATCACTATTTCGAGTCTCGG	303-324
271	GGGGCTGCCTACCCGTCCC	342-360
272	GTATGCGCAAATGACA	372-387
HPV 66
SEQ ID		Locus in
NO	5′→3′	HPV 66
273	CAGCTAAAAGCACAT	6680-6694
274	CAGCTAAAAGCACATTAACT	6680-6699
275	CTAAAAGCACATTAACTAAA	6683-6702
276	TTAACTAAATATGATGCCCG	6694-6713
277	CTAAATATGATGCCCGTGAA	6698-6717
278	TAAAATAACCTTAACTGCAGAAG	6777-6799
279	TAATACTTTATTAGACGAT	6825-6843
280	CTTATCCCCACCAGTTGCAACTAGCT	6855-6880
281	ATATAGGTATATTAAAAGCACA	6891-6912
282	GGAACAGCCCCCTGCAGAA	6930-6948
283	CCTGGCTAAATATAAG	6960-6975
HPV 67
SEQ ID		Locus in
NO	5′→3′	HPV 67
284	CTGAGGAAAAATCAG	6655-6669
285	GAGGAAAAATCAGAGGCTAC	6657-6676
286	ATCAGAGGCTACATACAAAAATG	6665-6687
287	AGGAAAAATCAGAGGCTACA	6658-6677
288	CTACATACAAAAATGAAAAC	6673-6692
289	CAAAATATCCCTTACTGCAAATG	6752-6774
290	TCCAGATATATTAGAGGAC	6800-6818
291	CCTTACACCACCTCCTTCAGGTAATT	6830-6855
292	ATATAGATTTGTTACCTCGCAG	6866-6887
293	AACATCCCCTCCAACAGCA	6905-6923
294	TCTTAAAAAGTACAGT	6935-6950
HPV 68
SEQ ID		Locus in
NO	5′→3′	HPV 68
295	CTACTACTGAATCAG	2653-2667
296	TGAATCAGCTGTACCAAATA	2660-2679
297	GAATCAGCTGTACCAAATAT	2661-2680
298	CAGCTGTACCAAATATTTATGA	2665-2686
299	ATATTTATGATCCTAATAAA	2677-2696
300	TCCTGCTATTTTGGATGAT	2804-2822
301	TACTATAACATTGTCCACTGATG	2756-2778
302	TGTTGCCCCTCCACCATCTGCTAGTC	2834-2859
303	ATACCGCTATCTGCAATCAGCA	2870-2891
304	AGACGCCCCTGCACCTACT	2909-2927
305	ATATGATGGCTTAAAC	2939-2954
HPV 69
SEQ ID		Locus in
NO	5′→3′	HPV 69
306	TATTAGTACTGTATCTGCAC	6572-6591
307	CTGTATCTGCACAAT	6580-6594
308	CTGTATCTGCACAATCTGCA	6580-6599
309	TGCACAATCTGCATCTGCCA	6587-6606
310	CAATCTGCATCTGCCACTTTTA	6591-6612
311	CCACTTTTAAACCATCAGAT	6604-6623
312	TAAAATTACTCTTACCACTGATG	6683-6705
313	TTCTACTATTTTGGAAAAT	6731-6749
314	CCTTACCTTGCCTCCTACTGCTAGTT	6761-6786
315	ATATAGGTTTATTAAAAATTCA	6797-6818
316	CGATGCCCCTGCACAGCCC	6836-6854
HPV 70
SEQ ID		Locus in
NO	5′→3′	HPV 70
317	TGTCTGCCTGCACCGAAACG	6614-6633
318	CTGCACCGAAACGGC	6621-6635
319	GAAACGGCCATACCTGCTGT	6628-6647
320	CGAAACGGCCATACCTGCTG	6627-6646
321	CGGCCATACCTGCTGTATATAG	6632-6653
322	CTGTATATAGCCCTACAAAG	6644-6663
323	TACTATCACATTAACTGCTGACG	6723-6745
324	TCCTGCAATTTTGGACAAT	6771-6789
325	AGTTACCCCTCCACCATCTGCAAGCT	6801-6826
326	GTATAGGTATTTACAATCAGCA	6837-6858
327	GGATGCTCCTACACCTGAA	6876-6894
328	CTATGACGATTTAAAA	6906-6921
HPV 72
SEQ ID		Locus in
NO	5′→3′	HPV 72
329	ATCTGTTGGTTTAATGAGCT	6759-6778
330	TTTGTGACAGTTGTAGATAC	6780-6799
331	CTGCCACAGCGTCCT	6829-6843
332	ACAGCGTCCTCTGTATCAGA	6834-6853
333	CCACAGCGTCCTCTGTATCA	6832-6851
334	AGCGTCCTCTGTATCAGAATAT	6836-6857
335	CAGAATATACAGCTTCTAAT	6850-6869
336	TAAAATTCACTTAACTCCTGAAA	6929-6951
337	TAAGGCCTTATTGGATGAC	6977-6995
338	TGTGGTGCCTCCTCCTTCTACCAGTT	7007-7032
339	CTATAGGTTTTTGCAGTCTCGT	7043-7064
340	GGGGGCTGCCACCCCTCCTCCT	7082-7103
341	ATATGCTAACTTATCC	7115-7130
HPV 74
SEQ ID		Locus in
NO	5′→3′	HPV 74
342	CCTACCTCACAATCG	1686-1700
343	CTCACAATCGCCTTCTGCTA	1691-1710
344	ACCTCACAATCGCCTTCTGC	1689-1708
345	CAATCGCCTTCTGCTACATATA	1695-1716
346	ACAATCGCCTTCTGCTACATAT	1694-1715
347	CTACATATAATAGTTCAGAC	1708-1727
348	TAGTATTAAGTTAACTGCTGAGG	1787-1809
349	TCCTACAGTTTTAGAAGAG	1835-1853
350	GCTAACGCCTCCCCCCAATGGTACTT	1865-1890
351	CTACAGATATGTGCAGTCCCAG	1901-1922
352	ACCTACGCCTGATAAAGCA	1940-1958
353	CTATGCAAATTTAAGT	1970-1985
HPV 82
SEQ ID		Locus in
NO	5′→3′	HPV 82
354	TGCTGTTACTCCATC	6608-6622
355	TGCTGTTACTCCATCTGTTG	6608-6627
356	ACTCCATCTGTTGCACAAAC	6615-6634
357	AAACATTTACTCCAGCAAAC	6631-6650
358	TAAAATCACTTTAACTACTGAAA	6710-6732
359	TTCTACAATTTTAGAACAG	6758-6776
360	ATTAACATTGCCCCCCTCCGCTAGTT	6788-6813
361	CTATCGATTTGTAAAAAATGCA	6824-6845
362	GGACAGTCCTCCACAGGCT	6863-6881
HPV CP8061
SEQ ID		Locus in
NO	5′→3′	HPV CP8061
363	TCTGTGCTACCAAAACTGTT	86-105
364	CTACCAAAACTGTTG	92-106
365	ACCAAAACTGTTGAGTCTAC	94-113
366	AACTGTTGAGTCTACATATAAA	99-120
367	GTTGAGTCTACATATAAAGC	103-122
368	CTACATATAAAGCCTCTAGT	110-129
369	TGTTATTAATTTAACAGCTGAAA	189-211
370	TGCTACATTACTGGAGGAC	237-255
371	GTTCTTACCACCTCCTACTG	267-286
372	CTACCGCTTTTTACAGTCTCAG	303-324
373	AAACAGTCCTCCTCCTGCAGAA	342-363
374	CTATGCAGATCTTACA	375-390
HPV CP8034
SEQ ID		Locus in
NO	5′→3′	HPV CP8034
375	CAGCTACATCTGCTG	92-106
376	GCTACATCTGCTGCTGCAGA	94-113
377	ACATCTGCTGCTGCAGAATACA	97-118
378	TGCTGCAGAATACAAGGCCT	105-124
379	GCTGCAGAATACAAGGCCTC	106-125
380	CAGAATACAAGGCCTCTAAC	110-129
381	TAAAATACAGTTAACACCAGAAA	189-211
382	CAAGGCACTGTTGGATGAT	237-255
383	TGTGTTGCCACCTCCTTCCACCAGTT	267-292
384	ATATCGCTTTTTACAGTCTCGG	303-324
385	GGGTGCTGCTGCCCCTGCGCCC	342-363
386	TTATGCCGACATGTCA	375-390
HPV L1AE5
SEQ ID		Locus in
NO	5′→3′	HPV L1AE5
387	ATCTACTGCAACTACTAATC	69-88
388	CTGCAACTACTAATC	74-88
389	CTGCAACTACTAATCCAGTT	74-93
390	ACTACTAATCCAGTTCCATCTA	79-100
391	CTAATCCAGTTCCATCTATA	83-102
392	CTATATATGAACCTTCTAAA	98-117
393	TAAAATTACACTTACTACTGATG	177-199
394	TCCTACTATTTTAGATAGT	225-243
395	TGTTAGTCCTCCCCCATCTGCTAGCT	255-280
396	ATATAGGTTTTTACAGTCATCT	291-312
397	GGATGTGGTTGTTCCACAA	330-348
HPV MM4
SEQ ID		Locus in
NO	5′→3′	HPV MM4
398	CTGCTGTTACTCAATCTGTT	92-111
399	TGCTGTTACTCAATC	93-107
400	GTTACTCAATCTGTTGCACA	97-116
401	TGCACAAACATTTACTCCAG	111-130
402	TTACTCAATCTGTTGCACAAAC	98-119
403	AAACATTTACTCCAGCAAAC	116-135
404	TAAAATCACTTTAACTACTGAAA	195-217
405	TTCTACAATTTTAGAACAG	243-261
406	ATTAACCTTGCCCCCCTCAGCTAGTT	273-298
407	CTATCGATTTGTAAAAAATGCA	309-330
408	GGACAGTCCTCCACAGGCT	348-366
HPV MM7
SEQ ID		Locus in
NO	5′→3′	HPV MM7
409	TGCTGCTACACAGGC	93-107
410	GCTGCTACACAGGCTAATGA	94-113
411	TGCTACACAGGCTAATGAAT	96-115
412	CTACACAGGCTAATGAATACAC	98-119
413	ATGAATACACAGCCTCTAAC	110-129
414	CAAAATACATCTTACCCCTGAAA	189-211
415	TGAACATTTATTGGATGAG	237-255
416	CGTGTTACCACCTCCTTCCACCAGCC	267-292
417	CTATCGCTATCTGCAGTCCCGT	303-324
418	GGGTCCTTCCGCCCCTGCCCCT	342-363
419	TTATGATGGCCTTGTA	375-390
HPV MM8
SEQ ID		Locus in
NO	5′→3′	HPV MM8
420	TGCTACCAACACCGA	93-107
421	CTACCAACACCGAATCAGAA	95-114
422	CCAACACCGAATCAGAATATAA	98-119
423	CAGAATATAAACCTACCAAT	110-129
424	TAAGGTCCGTCTGACTCCAGAGG	189-211
425	TGACTCCTTATTAGATGAG	237-255
426	TGTTGTGCCCCCTCCCTCCACAAGTT	267-292
427	CTATAGGTACTTGCAGTCTCGC	303-324
428	GGGGGCCGCCGCCGCCAAGCCT	342-363
429	TTATGCTGGCATGTCC	375-390

The sequences of the probes listed above are either identical or complementary to the corresponding sequences of HPV subtypes so that the probes can hybridize with the sequences of HPV subtypes perfectly.

According to a preferred embodiment of the present invention, a detector for detecting and simultaneously diagnosing 39 subtypes of human papilloma viruses (HPV) contained in a biological sample is provided. Please refer to FIG. 1. The detector 10 is an oligonucleotide biochip. The detector 10 includes a carrier 11 and a plurality of micro-dots 12 immobilized on the carrier 11. The carrier 11 is a nylon membrane. Each micro-dot 12 is used for identifying one particular HPV subtype. There is at least one oligonucleotide sequence contained in each micro-dot 12 that is specific to one particular HPV subtype. The oligonucleotide sequences are the probes selected from the above list for each HPV subtype respectively. For example, the probe on the carrier 11 could contain at least one sequence, which is selected from SEQ ID NO 1 to SEQ ID NO 12 (shown above), for identifying the subtype 6 of human papilloma viruses (HPV 6).

As described in the above, the probes will hybridize specifically with the L1 gene sequence of the corresponding HPV subtype. Preferably, the probes have a length between 15-30 bases. The oligonucleotide sequences contained in each micro-dot 12 serve as a detection probe, which hybridizes specifically with the L1 gene sequence of the particular HPV subtype to form a hybridization complex as a detection indicator. Therefore, each micro-dot 12 identifies a specific HPV subtype via a corresponding oligonucleotide of the specific HPV subtype, and thereby detecting and simultaneously identifying subtypes of human papilloma viruses. The sequences of the oligonucleotides provided by the present invention are specific to the epidemics of human papilloma viruses. The detector 10 is able to simultaneously identify 39 different HPV subtype that are HPV 6, HPV 11, HPV 16, HPV 18; HPV 26, HPV 31, HPV 32, HPV 33, HPV 35, HPV 37, HPV 39, HPV 42, HPV 43, HPV 44, HPV 45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 62, HPV 66, HPV 67, HPV 68, HPV 69, HPV 70, HPV 72, HPV 74, HPV 82, HPV CP8061, HPV CP8034, HPV L1AE5, HPV MM4, HPV MM7 and HPV MM8. Furthermore, the detector 10 includes the micro-dot 12 containing a Glutaldehyde-3-phosphodehydrogenase (GAPDH) gene, which is used as an internal control.

EXAMPLE I

The method for immobilizing or mounting the above mentioned probes (oligonucleotides) on the carrier 11 (the nylon membrane) is described as follows.

1.-TTTTTTTTTTTTTTT (SEQ ID NO 469) is added to the 3′ end of the oligonucleotide provided by the present invention by terminal transferase according to the following steps 1.1 to 1.3.

1.1 Mixing the following components:

	10X NEBuffer 4	5	μl
	2.5 mM CoCl2	5	μl
	oligonucleotide	5˜300	pmol
	10˜300 mM dATP, dCTP, dTTP or dGTP	1	μl
	Terminal Transferase (20 U/μl)	0.5˜5	μl
	(NEW English BioLabs, M0252S)
	Add M.Q. H2O to final volume	50	μl

1.2 The components are mixed at 37° C. for 15˜60 minutes.

1.3 10 μl of 0.2 M EDTA (pH 8.0) is added to the mixture to stop the reaction.

2. The oligonucleotide having 3′ end labeling is mounted on the carrier 11 according to the following steps 2.1 to 2.3.

2.1 The oligonucleotide having 3′ end labeling is mounted on the carrier 11 by a needle having a 400 μm wide head. The distance between each dot is 1200 μm.

2.2 The carrier 11 having the dot array 12 thereon is exposed to UV light, and the detector 10 is formed.

2.3 The detector 10 is preserved in a drying box.

EXAMPLE II

According to another preferred embodiment of the present invention, the carrier 11 could be a glass plate. The method for immobilizing or mounting the above mentioned probes (oligonucleotides) on the carrier 11 (glass plate) is described as follows.

1. The surface of the carrier 11 is treated according to the following steps 1.1 to 1.8.

1.1 The carrier 11 is cleaned in non-fluorescent and soft cleaner.

1.2 The clean carrier 11 is immersed in 10% NaOH.

1.3 The carrier 11 is oscillated in double-distilled water, 1% HCl solution and methanolin sequence for 2 minutes, and dried in an oven.

1.4 The carrier 11 is immersed in 1% 3-aminopropyltrimethoxysilane (APTMS) in 95% aqueous acetone at room temperature for about 2 minutes.

1.5 The carrier 11 is washed in acetone, and the carrier 11 is dried in the oven at 110° C. for 45 minutes.

1.6 The dried carrier 11 is immersed in 0.2% 1,4-phenylene diisothiocyanate, wherein the solvent is 10% pyridine in dimethyl formamide), at room temperature for 2 hours.

1.7 The carrier 11 is washed in methanol and acetone, and then the carrier 11 is dried.

1.8 The dried carrier 11 is preserved in a vacuum and dry box.

2. The oligonucleotides provided by the present invention are mounted on the carrier 11 (the glass plate) according to the following steps 2.1 to 2.3.

2.1 The oligonucleotide having 3′ end labeling is mounted on the carrier 11 by a needle having a 400 μm wide head. The distance between each dot is 1200 μm.

2.2 The carrier 11 is immersed in 1% NH₄OH solution for about 2 minutes, washed in double-distilled water, and then dried at room temperature. Thus, the detector 10 is formed.

2.3 The detector 10 is preserved in a dried box.

According to the above description, a biochip for specifically identifying the subtypes of human papilloma viruses contained in a biological sample is provided. Please refer to FIG. 2(a). The biochip 20 includes a carrier 21 and a plurality of micro-dots 22 immobilized on the carrier 21. The carrier 21 is a nylon membrane. The actual length of the nylon membrane is about 1.44 cm and the actual width of the nylon membrane is about 0.96 cm. The micro-dots 22 are mounted on the carrier 21 according to the foresaid method, wherein the distance between each dot is about 1.2 mm and the diameter of each dot is about 0.4 mm. Each micro-dot 22 contains at least one oligonucleotide (1530mer), and each micro-dot 22 is used for specifically identifying a specific HPV subtype. The sequence of the oligonucleotide is selected from the foresaid list.

The subtype of human papilloma viruses identified by each dot of the micro-dots 22 is illustrated in FIG. 2(b). SC (system control) presents the PCR product amplified from any subtype of human papilloma viruses and biotin-contained primer. NC (negative control) presents the plants DNA fragment irrelevant to HPV. IN (internal control) presents the sequence 5′-gcccagactgtgggtggcag-3′ (SEQ ID NO 470) of the housekeeping gene, Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). In sum, the biochip 20 provided in the present invention is able to detect and simultaneously identify 39 different HPV subtypes contained in the biological sample.

According to another preferred embodiment of the present invention, a method for detecting and simultaneously diagnosing 39 subtypes of human papilloma viruses (HPV) contained in a biological sample is provided. The steps are generally described as follows. First, the L1 gene fragment of human papilloma viruses (HPV) contained in the biological sample is amplified by polymerase chain reaction (PCR) using primers labeled with signaling substance. After the amplification product is obtained, it is hybridized with the detector 11 as describe above to form a hybridization complex. Then, the nonhybridized amplification product is removed from the detector 11. Next, the detector 11 is detected for the existence of the hybridization complex through detecting the signaling substance. The micro-dot 12 having the signaling substance shown thereon means a positive result that the biological sample contains the specific HPV subtypes recognized by the corresponding micro-dot 12. Ultimately, the HPV subtypes contained in the biological sample are thereby detected and simultaneously identified.

The method provided by the present invention for detecting and simultaneously identifying 39 subtypes of human papilloma viruses contained in a sample is described as follows.

EXAMPLE III

1. The biological sample obtained from the patient is treated according to the following steps 1.1 to 1.3.

1.1 The cells are centrifuged at 1,500 rpm at 20° C. for 5 minutes.

1.2 The cell pellet is washed in 10 mM Tris (pH 8.5) and dissolved in 8 mM NaOH. Then, the solution is transfer to 1.5 mL micro-tube.

1.3 A proper amount of TreTaq (1 U/μl) solution is added to the micro-tube. The reaction is carried out at 95° C. for 1 hour. The DNA contained in the sample is obtained after centrifugation at 13,500 rpm, 20° C. for 5 minutes. The otained DNA is preserved at −20° C.

EXAMPLE IV

2 The L1 gene fragment of human papilloma viruses (HPV) contained in the biological sample is then amplified by polymerase chain reaction (PCR). The polymerase chain reactions are performed according to the following steps.

2.1 Glutaldehyde-3-phosphodehydrogenase (GAPDH) gene is used as the internal control of the polymerase chain reactions so that it could help confirm whether the detecting protocols are precisely followed. The steps are described according to the following steps 2.1.1 to 2.1.3.

2.1.1 Mixing the following components:

			Final
Reagent	Stock	amount	concentration
Sterile H2O			2.6
10X Taq Buffer			0.5	1X Taq Buffer
dNTP	2.5	mM	0.4	200	μM
Template			1
GAP241-51) primer	10	pmol/μl	0.2	0.4	pmol/μl
GAP241-32) primer	10	pmol/μl	0.2	0.4	pmol/μl
ProTaq (PROTECH)	5	U/μl	0.1	0.1	U/μl
Total volume (μl)			5
1)Gap241-5 (SEQ ID NO 471): CCACCAACTGCTTAGCACCCC
2)Gap241-3 (SEQ ID NO 472): TGCAGCGTACTCCCCACATCA
3)The proper amount of mineral oil is added to prevent the evaporation.

2.1.2 The polymerase chain reaction is performed according to the following programs.

	Program 1	Program 2	Program 3
		94° C., 15 seconds
	94° C.,	57° C.,	72° C.,
	3 minutes	1 minute	5 minutes
		72° C., 30 seconds
		40 cycles

2.1.3 The product of the polymerase chain reaction is analyzed in 2.5% agarose/EtBr (0.5×TBE).

2.2 The DNA contained in the sample is amplified by the polymerase chain reaction according to the following steps.

2.2.1 Mixing the following components:

Reagent	Stock	Amount	Final concentration
Sterile H2O		4.7-5.7
10X Taq Buffer		1	1X Taq Buffer
dNTP	2.5 mM	0.8	200 μM
Template		1-2
BSA	10 mg/ml	0.1	0.1 μg/μl
Primer1,2)	10 pmol/μl	0.6	0.6 pmol/μl
Primer1,2)	10 pmol/μl	0.6	0.6 pmol/μl
ProTaq (PROTECH)	5 U/μl	0.2	0.1 U/μl
Total volume (μl)		10
1)MY09/MY11: Weimin et al., 1997, J. Clin. Microbiol. 35(6): 1304-1310
2)MY11/GP6+: Weimin et al., 1997, J. Clin. Microbiol. 35(6): 1304-1310
3) The proper amount of mineral oil is added to prevent the evaporation.
4) The 5′ end of the MY09 and GP6+ primers could be labeled with biotin or Cy5 fluorescent substances.

2.2.2 The polymerase chain reaction is performed according to the following programs.

	Program 1	Program 2	Program 3
		94° C., 45 seconds
	94° C.,	45° C.,	72° C.,
	3 minutes	1 minute	5 minutes
		72° C., 1.5 minutes
		45 cycles

2.2.3 The product of the polymerase chain reaction is analyzed in 2.5% agarose/EtBr (0.5×TBE).

According to the above description, the biochip 20 is used for identifying different HPV subtypes. In one embodiment of the invention, the positive clones of human papilloma viruses are used and detected according to the foresaid method. As previously mentioned, the PCR amplification product could be obtained by different primer sets. One is primer set MY09/MY11, the other is primer set MY11/GP6+. Therefore, the positive clones are respectively amplified by PCR using MY11/MY09 primers and MY11/GP6+ primers. The products of the polymerase chain reaction are analyzed in 2.5% agarose/EtBr, and the electrophoresis results are shown in FIG. 3(a)-(c). FIG. 3(a) shows the electrophoresis result of the analyzed PCR products using primer set MY09/MY11. In FIG. 3(a), M presents DNA marker. Lane 1˜20 present HPV 6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 33, HPV 35, HPV 44, HPV 45, HPV 52, HPV 53, HPV 54, HPV 56, HPV 59, HPV 61, HPV 66, HPV 70, HPV CP8061, and HPV L1AE5 in sequence. FIG. 3(b) shows the electrophoresis result of the analyzed PCR products using primer set MY11/GP6+. In FIG. 3(b), M presents DNA marker. Lane 1˜39 present HPV 6, 11, 16, 18, 26, 31, 32, 33, 35, 37, 39, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 72, 74, 82, CP8061, CP8304, L1AE5, MM4, MM7, and MM8 in sequence. FIG. 3(c) shows the electrophoresis result of the PCR products using GAPDH primer set. Clearly, the electrophoresis results show the PCR products with correct sizes. That is, PCR products using primer set MY09/MY11 is about 450 bp, the PCR products using primer set MY11/GP6+ is about 190 bp, and the PCR products using GAPDH primer set is about 190 bp.

EXAMPLE V

3. When the carrier 11 is a nylon membrane, the detector 10 provided by the present invention is used for identifying the subtypes of human papilloma viruses according to the following hybridization steps.

3.1 The detector 10 is immersed in 2×SSC solution for 5 minutes.

3.2 The detector 10 is immersed in a buffer containing salmon sperm DNA (50 μg/μl), and the oligonucleotides mounted on the detector 10 are pre-hybridized with the salmon sperm DNA at 35° C. for 30 minutes.

3.3 The PCR product having biotin labeled thereon is added into and mixed with a buffer containing salmon sperm DNA (50 μg/μl) at 95° C. for about 5 minutes. The denatured DNA is placed on ice.

3.4 The denature DNA is added to the detector 10 and hybridized with the oligonucleotides at 35° C. for 4 hours or overnight.

3.5 The detector 10 is washed in 2×SSC/1% SDS solution at 35° C. for 15 minutes.

3.6 The detector 10 is washed in 0.2×SSC/0.1% SDS solution at 35° C. for 15 minutes.

3.7 The detector 10 is treated in 0.5% isolation reagent for 1 hour.

3.8 The detector 10 is treated with avidin-alkalinephosphatase for about 1 hour.

3.9 The detector 10 is washed in 1×PBST solution.

3.10 The detector 10 is washed in Tris/NaCl solution.

3.11 The detector 10 is treated with NBT/BCIP at room temperature to show the reacting dot in blue.

3.12 The blue dot having the specific oligonucleotide sequence presents the specific subtype of human papilloma viruses contained in the sample.

Preferably, the foresaid PCR amplified products shown in FIGS. 3(a) and 3(b) are then respectively detected by the biochip 20 according to the above steps and the results are shown in FIGS. 4(a) and 4(b). FIG. 4(a) shows the detecting result of detecting the PCR products using primer set MY09/MY11 of HPV positive clones. FIG. 4(b) shows the detecting result of detecting the PCR products using primer set MY11/GP6+ of HPV positive clones. When comparing the results shown in FIG. 4(a) and FIG. 3(b) based on the “SC” dot, it is very clear that the biochip 20 can precisely identify the subtype of human papilloma viruses. Take the result of HPV 6 as example. Since this biochip is hybridized with the PCR product amplified from HPV 6 positive clone, there should be 6 positive micro-dots shown on the biochip 20, including 2 SC micro-dots at the corners, 2 SC micro-dots in the central, and 2 micro-dots of HPV 6. The result clearly shows the exact 6 positive micro-dots without any other false positive micro-dot. Obviously, all the results of other biochips in FIGS. 4(a) and 4(b) show a clear and clean result as well. In other words, there is no cross reaction occurred in the detection, which proves that the biochip provided in the present invention has a very high specificity.

In addition, in another embodiment of the invention, the biological sample obtained from the patient is used and detected. The biochip 20 and the detection method described in the above are used for detecting and identifying the HPV subtypes contained in the sample according to the foresaid method. The results are shown in FIG. 5. When comparing the results shown in FIG. 5 and FIG. 3(b) based on the “SC” dot, the results show that HPV 53 is contained in the sample (1), HPV 45 is contained in the sample (2), HPV 52 is contained in the sample (3), and HPV 39 is contained in the sample (4). Therefore, when detecting the biological sample obtained from a patient, it is very clear that the biochip 20 can precisely identify the subtype of human papilloma viruses.

EXAMPLE VI

According to another embodiment of the present invention, the carrier 11 could be a glass plate. When the carrier 11 is a glass plate, the detector 10 provided by the present invention is used for identifying the subtypes of human papilloma viruses according to the following hybridization steps.

4.1 The PCR product having Cy5 labeled thereon is purified by PCR Clean Up-M System (Viogene, USA), and the PCR product is precipitated in ethanol. Then, the PCR product is dried.

4.2 The precipitated DNA is dissolved in 12 μl of the buffer (2×SSC/0.1% SDS), and centrifugated for 1 minute, and then placed on boiled water for 2 minutes. Then, the mixture is placed on ice for 5 minutes.

4.3 The mixture is centrifugated for 30 seconds, and 10 μl of the mixture is added to the left side of the dot array 22. A cover slice is carefully covered on the dot array from the left side of the dot array to prevent the bubble formation. Then, the detector 10 is place in Humid Chamber (Sigma, USA), and the dot array is faces downward at 35° C. for 4 hours or overnight.

4.4 The detector 10 is vertically placed in the solution A (2×SSC/1% SDS), and the detector is slightly oscillated apart from the cover slice. Then, the detector 20 is washed in a shaker at 160 rpm for 12 minutes.

4.5 The detector 10 is washed in the solution B (0.2×SSC/0.1% SDS) and oscillated at 35° C. for 12 minutes. The detector 10 is washed in water. Then the detector 10 is dried.

4.6 The dried detector 10 is scanned by GenePix™4000 (Axon, USA), excited by the light having 635 nm of wavelength, and analyzed by GenePixPro 3.0 (Axon, USA).

According to the above description, a biochip for specifically identifying the subtypes of human papilloma viruses contained in a biological sample is provided. Please refer to FIGS. 6(a) and (b). The biochip 30 includes a carrier 31 and a plurality of micro-dots 32 immobilized on the carrier 31. The carrier 31 is a glass plate. The micro-dots 32 are immobilized on the glass plate 31 according to the foresaid method. Each micro-dot 32 contains at least one oligonucleotide (1530mer), and each micro-dot 32 is used for specifically identifying a specific HPV subtype. The sequence of the oligonucleotide is selected from the foresaid list. The subtype of human papilloma viruses identified by each dot of the micro-dots 32 is illustrated in FIG. 6(b).

The biochip 30 is stained with SYBR Green II, scanned by GenePix™ 4000 (Axon, USA) and excited by the light having 635 nm of wavelength. The result is shown in FIG. 7(a). Preferably, the foresaid PCR amplified products are then detected by the biochip 30 according to the above steps and the results are shown in FIGS. 7(b). When comparing the results shown in FIG. 7(a) and FIG. 6(b), it is very clear that the biochip 30 can precisely identify the subtype of human papilloma viruses. The result clearly shows the exact positive micro-dots without any other false positive micro-dot. Besides, there is no cross reaction occurred in the detection, which proves that the biochip provided in the present invention has a very high specificity. Therefore, the biochip having different carriers (made of nylon membrane or glass plate) can obtain the same results and same specificities.

According to the above, the drawbacks in the conventional HPV detecting kit do not exist in the HPV detecting kit provided in the present invention. The HPV detecting kit of the present invention is able to diagnose multiple HPV subtypes (up to 39 different subtypes) at the same time, allowing the rapid and reliable detection and identification of HPV possibly present in a biological sample. Besides, an internal control is included in the detector to show whether the detecting process is well handled so that the detecting result is dependable. In addition, HPV detecting kit of the present invention has a high specificity and accuracy. Hence, the present invention not only has a novelty and a progressive nature, but also has an industry utility.

While the invention has been described in terms of what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention needs not be limited to the disclosed embodiments. On the contrary, it is intended to cover various modifications and similar arrangements included within the spirit and scope of the appended claims which are to be accorded with the broadest interpretation so as to encompass all such modifications and similar structures.

Claims

1. A detector for detecting and simultaneously diagnosing at least one subtype of human papilloma viruses (HPV) contained in a biological sample, comprising: a carrier; a plurality of micro-dots immobilized on said carrier, wherein each micro-dot is for identifying one particular HPV subtype, and said HPV subtype is one selected from a group consisting of (HPV 6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 32, HPV 33, HPV 35, HPV 37, HPV 39, HPV 42, HPV 43, HPV 44, HPV 45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 62, HPV 66, HPV 67, HPV 68, HPV 69, HPV 70, HPV 72, HPV 74, HPV 82, HPV CP8061, HPV CP8034, HPV L1AE5, HPV MM4, HPV MM7 and HPV MM8); and at least one oligonucleotide sequence contained in each said micro-dot that is specific to said one particular HPV subtype; wherein said at least one oligonucleotide sequence serves as a detection probe that hybridizes specifically with an L1 gene sequence of said one particular HPV subtype to form a hybridization complex as a detection indicator, so that each micro-dot identifies one particular HPV subtype via a corresponding oligonucleotide of said one particular HPV subtype, and thereby detecting and simultaneously identifying subtypes of human papilloma viruses.

2. The detector according to claim 1, wherein said at least one oligonucleotide that hybridizes specifically with an L1 gene sequence of said one particular HPV subtype is respectively chosen from the following list for each HPV subtype: (SEQ ID NO:1-SEQ ID NO:12) for HPV 6, (SEQ ID NO:13-SEQ ID NO:24) for HPV 11, (SEQ ID NO:25-SEQ ID NO:36) for HPV 16, (SEQ ID NO:37-SEQ ID NO:48) for HPV 18, (SEQ ID NO:49-SEQ ID NO:58) for HPV 26, (SEQ ID NO:59-SEQ ID NO:68) for HPV 31, (SEQ ID NO:69-SEQ ID NO:79) for HPV 32, (SEQ ID NO:80-SEQ ID NO:90) for HPV 33, (SEQ ID NO:91-SEQ ID NO:100) for HPV 35, (SEQ ID NO:101-SEQ ID NO:112) for HPV 37, (SEQ ID NO:113-SEQ ID NO:123) for HPV 39, (SEQ ID NO:124-SEQ ID NO:133) for HPV 42, (SEQ ID NO:134-SEQ ID NO:143) for HPV 43, (SEQ ID NO:144-SEQ ID NO:154) for HPV 44, (SEQ ID NO:155-SEQ ID NO:165) for HPV 45, (SEQ ID NO:166-SEQ ID NO:177) for HPV 51, (SEQ ID NO:178-SEQ ID NO:189) for HPV 52, (SEQ ID NO:190-SEQ ID NO:199) for HPV 53, (SEQ ID NO:200-SEQ ID NO:209) for HPV 54, (SEQ ID NO:210-SEQ ID NO:218) for HPV 55, (SEQ ID NO:219-SEQ ID NO:228) for HPV 56, (SEQ ID NO:229-SEQ ID NO:239) for HPV 58, (SEQ ID NO:240-SEQ ID NO:250) for HPV 59, (SEQ ID NO:251-SEQ ID NO:261) for HPV 61, (SEQ ID NO:262-SEQ ID NO:272) for HPV 62, (SEQ ID NO:273-SEQ ID NO:283) for HPV 66, (SEQ ID NO:284-SEQ ID NO:294) for HPV 67, (SEQ ID NO:295-SEQ ID NO:305) for HPV 68, (SEQ ID NO:306-SEQ ID NO:316) for HPV 69, (SEQ ID NO:317-SEQ ID NO:328) for HPV 70, (SEQ ID NO:329-SEQ ID NO:341) for HPV 72, (SEQ ID NO:342-SEQ ID NO:353) for HPV 74, (SEQ ID NO:354-SEQ ID NO:362) for HPV 82, (SEQ ID NO:363-SEQ ID NO:374) for HPV CP8061, (SEQ ID NO:375-SEQ ID NO:386) for HPV CP8034, (SEQ ID NO:387-SEQ ID NO:397) for HPV L1AE5, (SEQ ID NO:398-SEQ ID NO:408) for HPV MM4, (SEQ ID NO:409-SEQ ID NO:419) for HPV MM7, and (SEQ ID NO:420-SEQ ID NO:429) for HPV MM8.

3. The detector according to claim 1, wherein said carrier is a nylon membrane.

4. The detector according to claim 1, wherein said carrier is a glass plate.

5. The detector according to claim 1, wherein said detector is an oligonucleotide biochip.

6. The detector according to claim 1, wherein said at least one oligonucleotide has a length between 15-30 bases.

7. The detector according to claim 1 further comprising a micro-dot containing a Glutaldehyde-3-phosphodehydrogenase (GAPDH) gene, which is used as an internal control.

8. A method for detecting and simultaneously diagnosing at least one subtype of human papilloma viruses (HPV) contained in a biological sample, comprising steps of: amplifying an L1 gene fragment of human papilloma viruses (HPV) contained in said biological sample and obtaining an amplification product by polymerase chain reaction (PCR) using primers labeled with signaling substance; hybridizing said amplification product with a detector according to claim 1 to form a hybridization complex; removing nonhybridized said amplification product; and detecting said hybridization complex through detecting said signaling substance, thereby detecting and simultaneously identifying HPV subtypes contained in said biological sample.

9. The method according to claim 8, wherein said amplification product has a length of 450 base pairs by using MY09 as sense primer and MY11 as anti-sense primer in polymerase chain reaction (PCR).

10. The method according to claim 8, wherein said amplification product has a length of 190 base pairs by using MY11 as sense primer and GP6+as anti-sense primer in polymerase chain reaction (PCR).

11. The method according to claim 8, wherein said signaling substance is biotin.

12. The method according to claim 11, wherein said biotin reacts with avidin-alkalinephosphatase to show said hybridization result by presenting a particular color.

13. The method according to claim 8, wherein said signaling substance is a fluorescent substance.

14. The method according to claim 13, wherein said fluorescent substance is Cyanine 5.

15. A probe which hybridizes to nucleic acid from an HPV subtype, said probe being selected from the group consisting of: SEQ ID NO:1-SEQ ID NO:12 and sequences fully complementary thereto, which hybridize with HPV 6; SEQ ID NO:13-SEQ ID NO:24 and sequences fully complementary thereto, which hybridize with HPV 11; SEQ ID NO:25-SEQ ID NO:36 and sequences fully complementary thereto, which hybridize with HPV 16; SEQ ID NO:37-SEQ ID NO:48 and sequences fully complementary thereto, which hybridize with HPV 18; SEQ ID NO:49-SEQ ID NO:58 and sequences fully complementary thereto, which hybridize with HPV 26; SEQ ID NO:59-SEQ ID NO:68 and sequences fully complementary thereto, which hybridize with HPV 31; SEQ ID NO:69-SEQ ID NO:79 and sequences fully complementary thereto, which hybridize with HPV 32; SEQ ID NO:80-SEQ ID NO:90 and sequences fully complementary thereto, which hybridize with HPV 33; SEQ ID NO:91-SEQ ID NO:100 and sequences fully complementary thereto, which hybridize with HPV 35; SEQ ID NO:101-SEQ ID NO:112 and sequences fully complementary thereto, which hybridize with HPV 37; SEQ ID NO:113-SEQ ID NO:123 and sequences fully complementary thereto, which hybridize with HPV 39; SEQ ID NO:124-SEQ ID NO:133 and sequences fully complementary thereto, which hybridize with HPV 42; SEQ ID NO:134-SEQ ID NO:143 and sequences fully complementary thereto, which hybridize with HPV 43; SEQ ID NO:144-SEQ ID NO:154 and sequences fully complementary thereto, which hybridize with HPV 44; SEQ ID NO:155-SEQ ID NO:165 and sequences fully complementary thereto, which hybridize with HPV 45; SEQ ID NO:166-SEQ ID NO:177 and sequences fully complementary thereto, which hybridize with HPV 51; SEQ ID NO:178-SEQ ID NO:189 and sequences fully complementary thereto, which hybridize with HPV 52; SEQ ID NO:190-SEQ ID NO:199 and sequences fully complementary thereto, which hybridize with HPV 53; SEQ ID NO:200-SEQ ID NO:209 and sequences fully complementary thereto, which hybridize with HPV 54; SEQ ID NO:210-SEQ ID NO:218 and sequences fully complementary thereto, which hybridize with HPV 55; SEQ ID NO:219-SEQ ID NO:228 and sequences fully complementary thereto, which hybridize with HPV 56; SEQ ID NO:229-SEQ ID NO:239 and sequences fully complementary thereto, which hybridize with HPV 58; SEQ ID NO:240-SEQ ID NO:250 and sequences fully complementary thereto, which hybridize with HPV 59; SEQ ID NO:251-SEQ ID NO:261 and sequences fully complementary thereto, which hybridize with HPV 61; SEQ ID NO:262-SEQ ID NO:272 and sequences fully complementary thereto, which hybridize with HPV 62; SEQ ID NO:273-SEQ ID NO:283 and sequences fully complementary thereto, which hybridize with HPV 66; SEQ ID NO:284-SEQ ID NO:294 and sequences fully complementary thereto, which hybridize with HPV 67; SEQ ID NO:295-SEQ ID NO:305 and sequences fully complementary thereto, which hybridize with HPV 68; SEQ ID NO:306-SEQ ID NO:316 and sequences fully complementary thereto, which hybridize with HPV 69; SEQ ID NO:317-SEQ ID NO:328 and sequences fully complementary thereto, which hybridize with HPV 70; SEQ ID NO:329-SEQ ID NO:341 and sequences fully complementary thereto, which hybridize with HPV 72; SEQ ID NO:342-SEQ ID NO:353 and sequences fully complementary thereto, which hybridize with HPV 74; SEQ ID NO:354-SEQ ID NO:362 and sequences fully complementary thereto, which hybridize with HPV 82; SEQ ID NO:363-SEQ ID NO:374 and sequences fully complementary thereto, which hybridize with HPV CP8061; SEQ ID NO:375-SEQ ID NO:386 and sequences fully complementary thereto, which hybridize with HPV CP8034; SEQ ID NO:387-SEQ ID NO:397 and sequences fully complementary thereto, which hybridize with HPV L1AE5; SEQ ID NO:398-SEQ ID NO:408 and sequences fully complementary thereto, which hybridize with HPV MM4; SEQ ID NO:409-SEQ ID NO:419 and sequences fully complementary thereto, which hybridize with HPV MM7; and SEQ ID NO:420-SEQ ID NO:429 and sequences fully complementary thereto, which hybridize with HPV MM8.